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Abstract 
North West Tasmania is a vast and remote region with an ageing population. Since elderly 
people are prone to cancers and chronic diseases, the need for healthcare services in rural and 
remote communities is undoubtedly high, especially in the area of palliative care.  
It has been reported that access to optimal healthcare for rural and remote area patients has been 
problematic and many are receiving suboptimal palliative care services. Furthermore, drug-
related problems (DRPs) are commonly experienced by patients receiving palliative care; thus an 
efficient and quality assured standard of palliative care service is needed. We proposed that the 
inclusion of a pharmacist could be beneficial for palliative care services in North West 
Tasmania.  
The main aim of this study was to explore the role of pharmacist participation in community-
based palliative care services in North West Tasmania. Specific objectives were to investigate 
the nature and extent of DRPs in palliative care patients in North West Tasmania. 
We conducted the study in two parts; we commenced by retrospectively examining and 
identifying DRPs from the North West palliative care home-based patients’ medication records 
and then conducted a focus group discussion to gather opinions from the palliative care 
providers.  
In the first part of the study, apart from the collection of data related to DRPs, we collected 
information including patient demographics, medications, medical history and relevant 
laboratory data. 
The patients admitted under the palliative team care were reviewed. Their first three clinical 
assessments and the medication management of the patients were screened for potential and 
actual DRPs. For DRP assessment, the researchers first identified the symptoms as recorded in 
the medical notes. DRPs were then categorised using the D.O.C.U.M.E.N.T classification system 
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and their possible causes determined. 
The first part of the study involved 100 patients. The median age of participants was 68 years. 
Two-thirds of patients were male, and lung cancer was the most prevalent cancer diagnosis. We 
found that 52% of our patient sample experienced DRPs when their admission data was assessed. 
Using the D.O.C.U.M.E.N.T classification system, our findings indicated that the most common 
DRPs were drug toxicity, dosage problems and patient non-compliance.  Dosage 
mismanagement and patient noncompliance were common contributing factors of DRPs among 
patients. These unwanted outcomes were mainly due to polypharmacy, when the patients were 
following multiple medication regimen for chemotherapy and chronic diseases. The study also 
found that opioid analgesics, benzodiazepines and anti-nausea medications were common causes 
of DRPs. 
In the second part of the study, a focus group discussion was conducted to gather opinions from 
the North West palliative care team. The focus group was conducted with 14 participants to 
discuss 3 main topics: (1) DRPs encountered during work, (2) experiences to overcome DRPs, 
(3) opinions about the inclusion of a pharmacist in the team and barriers to implementation.
Opinions concerning the team members’ experiences of DRPs and their management, and the 
potential role of a pharmacist on the team were shared and recorded. All qualitative data were 
audiotaped, transcribed and later analysed using thematic analysis. 
Participants described patients’ drug misadventure, inadequate drug supply, minimal patients 
education, lack of drug interventions and medication reviews as the main contributing factors of 
DRPs. During their community- based palliative care practices, they would also rely on 
GP/pharmacist advice when they needed access drug information. They also participated in 
regular group review to enhance their knowledge in DRPs management. 
Several measures were discussed to either prevent or resolve DRPs and their consequences in 
order to achieve the best possible outcomes for the patients. The involvement of a pharmacist in 
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palliative care, such as pharmacist-conducted home medicines reviews (HMRs) for patients 
receiving palliative care, were suggested to prevent or manage DRPs. The participants also 
affirmed the value of an inclusion of pharmacist in the team, as pharmacist involvement was 
expected to improve patients’ medication management and minimise related errors, and at the 
same time increased the medication-related knowledge of team members and patients. The main 
barriers to the implementation of a pharmacist-participated palliative care team were funding and 
State health service policy. 
The challenges faced by the palliative care team members in this region have highlighted the 
need of a palliative care pharmacist. The inclusion of a pharmacist was considered to be 
beneficial to form a multidisciplinary team to support community-based palliative care service, 
but requires government funding and support. 
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1 Introduction 
 
1.1 Palliative care 
1.1.1 What is palliative care 
The World Health Organization (WHO) describes palliative care as "an approach that improves 
the quality of life of patients and their families facing the problems associated with life-
threatening illness, through the prevention and relief of suffering by means of early identification 
and impeccable assessment and treatment of pain and other problems, physical, psychosocial and 
spiritual." [1]. The word palliative is derived from the Latin word ‘palliare’, meaning to cloak, to 
shield or to alleviate [2,3]. The aim of palliative care, therefore, is to cloak and reduce the 
noxious symptoms of advancing diseases, rather than to cure or reverse the progressive 
deterioration of the diseases [3]. 
Palliative care has been practiced in Australia since the 1980s. It started from a community-led 
call to recognise the needs of people who were dying and their families, and to provide services 
to address these needs [4]. In 2009-10, there were almost 56,000 patients under palliative care 
treatment reported from public and private hospitals in Australia [4]. This is an increase of 51% 
from the 2000-01 period. 
 
In 2001-02, more than 1 in 5 (23.3%) hospital admitted patients had been palliative care patients 
[5]. This proportion has steadily increased to 1 in 3 (37.2%) people who died as an admitted 
patient receiving palliative care services (Figure 1) over the past decade. 
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Figure 1. Data showing increasing number of admitted patients who received palliative care services [5] 
 
The most recent Tasmanian data available, from the University of Wollongong’s Centre for 
Health Services Development, showed that the number of palliative care referrals across the 
State increased by 205 (28.5%) between 2000/01 and 2002/03 [Figure 2]. The number of 
admissions grew by 83 (11.5%) in 2002/03.With an ageing population and the highest overall 
incidence of cancer in Australia, there is expected to be an increasing demand for palliative care 
services [6]. 
 
 
Figure 2. Data showing the summary of community based palliative care service 2001/02-2002/03 [6] 
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1.1.2 The principles of palliative care 
WHO states that good palliative care should [1]: 
•       provide relief from pain, shortness of breath, nausea and other distressing symptoms; 
•       affirm life and regards dying as a normal process; 
•       intend neither to hasten nor to postpone death; 
•       integrate the psychological and spiritual aspects of patient care; 
•       offer a support system to help patients live as actively as possible; 
•       offer a support system to help the family cope; 
•       use a team approach to address the needs of patients and their families; 
•       enhance quality of life; and 
•       be applicable early in the course of illness, in conjunction with other therapies that are 
intended to prolong life, such as chemotherapy or radiation therapy. 
The objective of palliative care is to provide the best possible quality of life, both for people 
approaching the end of life and for their families and carers [3]. Cicely Saunders [7], who was 
well known as the founder of modern hospice, advocated that as a palliative care health provider, 
one should stress the idea of ‘Total Pain’ relief, which is a holistic approach to provide an “active 
and total” care and support to patients whose disease is not responsive to curative treatment. 
Palliative care addresses patients’ physical symptoms and at the same time, takes into account 
their emotional, psychological and spiritual needs.  
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1.1.3 The focus of palliative care 
Palliative care should not only be offered when disease-specific treatment has failed, since it is 
perfectly applicable during the early stage of illness, in conjunction with other therapies that are 
implemented to prolong life.  
Some of the common medical conditions of people requiring palliative care include: cancer, 
HIV/AIDS, motor neurone disease, muscular dystrophy, multiple sclerosis and end-stage 
dementia [1]. These are mainly incurable malignant chronic diseases that require regular medical 
attention and in many circumstances, patients’ health progressively deteriorates. These patients 
require regular and formal clinical process of patient-appropriate assessment, diagnosis, 
planning, interventions, monitoring, and follow-up [8]. 
According to the Worldwide Palliative Care Alliance Policy (WPCA), which endorsed and 
elaborated the WHO definition of palliative care [9], the WHO definition is a description of 
compassionate, comprehensive palliative care that can be provided in any geopolitical, cultural 
and economic setting. However, in reality, many health care professionals and people still view 
palliative care as being limited to care of the dying in hospice and hospitals. This perception 
results in restricted access to palliative care for many people who could receive significant 
benefits from this care earlier in their illnesses and in their preferred care setting. 
A good palliative service provider should integrate psychological and spiritual care to care for 
patients. One should not hasten or postpone the death of the deteriorated patients as cure is not 
the aim of the treatment. A good palliative care service offers a support system to help patients 
live as actively as possible until their death and in the environment of their choice.  
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One of the objectives of palliative care is focusing on pain and symptoms management, as pain 
relief and freedom from serious symptoms allows people to live as fully as possible for as long 
as possible. The service is not only for patients, but also for their family members and carers.  It 
is important to note that support for carers is an essential part of palliative care, whether to 
family members or professional carers. Palliative care helps to support the family cope during 
the patient’s illness and their own bereavement after death.  
In summary, palliative care can, and should, be instituted as a specialised medical care aim for 
people with serious illnesses whether or not there is hope of a cure [1]. It should be administered 
as a team approach and available at all levels of care (primary or specialised, private or public), 
appropriate for any patient at any age in any care setting (patient’s own home, a care facility, 
hospice, hospital) [10,11]. 
The core structures of palliative care are illustrated in the following diagram (Figure 3). 
     
 
Figure 3. The core structures of palliative care [3]  
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1.2 Palliative care and interdisciplinary approaches 
 
WHO claims that in order to effectively provide palliative care, it is necessary to include the 
patients’ family members and make use of any available community resources to the extent that 
palliative care can be implemented in all settings. WHO states that even when the resources are 
limited, as long as it is done with a multidisciplinary approach, palliative care should be able to 
be effectively implemented [1]. 
 
Palliative care is best delivered using an interdisciplinary approach [10]. This is often referred to 
as the holistic approach, and it is patient and family-centred [3]. Family and carers are seen as 
equal members of the palliative care team [11]. The purpose of the palliative care 
interdisciplinary team is to bring together the individual strengths of each professional to support 
and address the multi-faceted nature of the patients’ needs. The collaborative expertise from 
different healthcare professionals working together to achieve a comprehensive patient care that 
considers the physical, emotional, social, economic and spiritual needs of the person [11]. 
 
Without an interdisciplinary approach, it is unrealistic to expect one profession or individual to 
have the skills to make the necessary assessment, conduct the interventions, and provide ongoing 
monitoring [12].  
 
1.2.1 Interdisciplinary or multidisciplinary? 
 
The words ‘interdisciplinary’ and ‘multidisciplinary’ are often used interchangeably, but 
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according to Palliative Care Australia [13], "interdisciplinary team" is the preferred term.  
 
A multidisciplinary team might consist of health providers such as general practitioners, 
surgeons, medical or radiation oncologists, palliative care specialists, pastoral care workers, 
nurses, pharmacists, social workers, occupational therapists, physiotherapists, dieticians, and 
volunteers. These different disciplines use a care team approach to make decisions regarding 
diagnosis, treatment planning and other aspects of care for individual patients in order to provide 
a comprehensive care [14]. An interdisciplinary team is a team of providers who work together 
to develop and implement a plan of care. Team members vary depending on the services required 
to identify and address the expectations and needs of the patient, including their carers and 
family members.  
 
As suggested by Jessup [15], interdisciplinary teams have some advantages over 
multidisciplinary teams. The most obvious is the patient-centred approach. Interdisciplinary 
teams integrate separate discipline approaches into a single consultation. The team conducts all 
care plan designs and management goals with the patient together. The patient is intimately 
involved in any discussions regarding their condition or prognosis and the plans regarding their 
care. A common understanding and holistic view of all aspects of the patient’s care is ensured. 
Furthermore, interdisciplinary teams provide a stimulating work environment in which different 
disciplines can conduct some of the assessments and interventions with each other. In this way, 
different disciplines will learn from each and knowledge and skills are shared for the benefits of 
their patients.  
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1.2.2 Benefits of interdisciplinary approaches to palliative care 
 
Interdisciplinary approaches emphasise regular team meetings by the different professional 
disciplines to discuss the treatment plan for a patient by reviewing their physical, supportive care 
and emotional needs. These meetings are attended by a variety of health professionals who will 
differ depending on the type of non-curable diseases under discussion [16]. Strasser et al [17] 
showed that there was a reduction of the physical and psychological distress of patients with 
advance cancer when the patients were treated with an interdisciplinary approach and, at the 
same time, the patients also showed a high level of satisfaction. Other benefits of this care model 
are better patient survival rates, reduced costs for the healthcare facility and shorter waiting time 
to treatment [18]. 
 
A good interdisciplinary team practice requires effective planning and decision-making, in order 
to deliver quality patient care. Nancarrow et al (19) stated there were challenges faced by 
interdisciplinary team practice.  One typical example was the reluctance of health professionals 
to share responsibilities and knowledge to other professionals with different kinds and levels of 
education.  
 
 
1.3 The ageing population and problems in providing palliative care 
 
Australia’s population is ageing; in 2001, 13.7% of Australians were aged over 65 and 1.6% 
were over 85. By 2056, it is estimated that 25% will be over 65 and 5-7% will be over 85 [20]. 
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Cancer is predominantly a disease of older people [21]. It is estimated approximately 60% of all 
cancers and 70% of cancer mortality occur in people aged 65 years and over [22]. Cancer 
incidence increases with age, and because the population that is elderly is growing, the number 
of elderly patients with cancer will continue to increase. The national voice and peak body for 
palliative care in Australia, Palliative Care Australia [23] states that cancer is the most common 
principal diagnosis related to palliative care. In 2008-2009, approximately 60% of those reported 
to palliative care service were cancer related cases. It is prudent that the ageing population 
receives optimal palliative care services even though there are many barriers existed in the 
rural/regional community-based setting. 
 
1.3.1 Physiologic ageing and pharmacokinetics/pharmacodynamics changes 
The ageing process is characterised by structural and functional changes [24]. The majority of 
elderly patients are likely to have some degree of age-related pharmacokinetic changes. 
Physiological changes associated with ageing may alter the pharmacokinetics and 
pharmacodynamics of drug metabolism, which, in turn, decreasing their therapeutic index and 
increasing the risks of toxicity and drug-drug interactions [24]. 
 
Besides the changes in drug pharmacokinetic properties, sometimes significant 
pharmacodynamics changes also occur which tend to increase sensitivity to drugs. The changes 
in body composition, together with hepatic and renal impairment are responsible for an increase 
in the volume of distribution of lipid soluble drugs and reduced clearance of lipid soluble and 
water soluble drugs, respectively. All these changes lead to a prolongation of plasma elimination 
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half-life [24]. 
 
One of the most important changes to occur which influences the pharmacokinetics of many 
drugs is the progressive decline of renal function in elderly patients. Drugs are excreted at a 
slower rate and a lower dose may need to be prescribed. The progressive decline in glomerular 
filtration rate that occurs in elderly patients can lead to accumulation of opioid metabolites. 
Therefore, regular palliative medicine such as opioid analgesics should be monitored closely in 
the elderly patients. 
 
There are other factors which make an older patients more vulnerable to drug interactions. The 
activity of the cytochrome P450 system (CYP) decreases with age, which in turn increases the 
risk of drug interactions in many elderly patients [25]. Older patients also experience age related 
changes in body fat that can affect the metabolism of medications as well as the absorption of 
transdermal preparations. Reduced liver function, reduced absorption from the gastrointestinal 
tract, reduced cardiac output and altered body composition also occur with ageing. These 
alterations cause changes in drug bioavailability, distribution and elimination [25]. 
 
It is widely recognised that changes in pharmacokinetics and pharmacodynamics of cancer 
therapy as a result of aging, together with polypharmacy, may have an impact on drug–drug 
interactions and adverse drug events in the elderly [26]. Careful clinical assessment and patient 
monitoring during palliative care is crucial to achieve a satisfactory outcome. 
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1.3.2 Comorbidities 
 
Older cancer patients often have many health concerns. The risks of drug related problem 
become a concern when elderly patients with metastatic cancer continue to take medications for 
the primary and secondary prevention of concomitant comorbidities such as hypertension, 
cardiovascular disease, diabetes, osteoarthritis [27, 28, 29]. The risk of a serious adverse drug 
reactions increases as more drugs are taken for different chronic diseases [29]. This situation 
may potentially impair the patient’s quality of life and compromise anti-cancer and symptom 
control medication. Adherence to drug regimens also decreases as the number of drugs 
prescribed increases, meaning that anti-cancer and symptom control medication may not be 
taken because of the complexity and cost of multiple medications. There are several other factors 
that disrupt patient’s quality of life such as the monitoring of the effects of medications given for 
co-morbidities (cholesterol levels and blood pressure), the costs of complex medications and the 
chances of developing unwanted drug related issues [29]. 
 
1.3.3 Polypharmacy 
 
The presence of comorbidities often leads to polypharmacy, which is the use of multiple 
medications by a single patient and is commonly observed among elderly patients [30]. It is 
usually defined as the use of five or more drugs, including prescribed, over the counter, and 
complementary medicines [31]. Hilmer found that the incidence of adverse drug effects increases 
with the number of medications used [31]. Polypharmacy is also a barrier to patients’ compliance 
with medications because they are encountering complex medication regimens, increased risk of 
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adverse drug events and higher medication costs [31]. Although polypharmacy can be an issue in 
any age group, it can especially be a problem for the elderly, who consume more medications 
than any other patient group. Extermann in his studies suggested older cancer patients need to be 
assessed for more than just their cancer status [21].  
Elderly patients are more likely to receive multiple drugs for their diseases and the addition of 
more drugs for the relief of symptoms increases the risk of drug interactions, undesirable effects 
and may affect adherence. Other contributing factor such as the increased availability of over-
the-counter and herbal supplements for self-treatment can all contribute to polypharmacy [30, 
31]. 
Apart from elderly patients who are more likely to experience polypharmacy, Currow et al found 
that among the majority of people admitted to palliative care services, the number of prescribed 
medications increased as death approached, with reductions in long-term medications often 
surpassed by initiation of drugs for symptom management [32]. 
 
1.3.4 Drug related problems 
 
A drug related problem (DRP) is defined as “an undesirable patient experience that involves drug 
therapy and that actually or potentially interferes with the desired outcome of medical care [33]. 
Many medications used commonly in palliative care  such as opioid analgesics, benzodiazepines 
and antidepressants contribute to the risk of DRPs occurring in palliative care patients [34]. 
These medications require careful clinical administration and monitoring. 
DRPs are common in the palliative care setting; Lee et al [35] reported a prevalence of DRPs 
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such as underdosage, untreated indication and patients’ failure to take or receive drugs. The data 
in this study were collected by two palliative care pharmacists over a period of 3 months to 
record any DRPs encountered by the patents during the study.  
The table below shows the prevalence of common DRPs experienced by patients receiving 
palliative care [35].  
 
Table 1. The prevalence of symptoms in palliative care patients [34]. 
It is also important for palliative care health providers to be careful with patients who are taking 
off-label and over-the-counter medications (including complementary and alternative 
medicines), as they may also potentially lead to DRPs [36]. 
Optimising medication-related outcomes has become an important goal of care for palliative care 
health providers, particularly in the community setting. Medication management needs to be 
carried out effectively to reduce or eliminate symptoms, stop or slow a disease progress, or 
prevent a disease or symptom. Inadequate medication management often results from poor 
medication-related knowledge by patients and their family members, which potentially gives rise 
to medication noncompliance.  Medication misadventure and adverse events (as shown in Table 
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1) may result in hospital admission. Therefore, quality of palliative care needs to be enhanced, 
whereby patients are able to be treated with health professionals with drug expertise.  
 
1.3.5 Undertreatment and deprescribing 
 
Undertreatment and deprescribing are two important issues for both primary care and also 
specialist prescribers to address during palliative care.  
 
Pain is a major healthcare problem for cancer patients. Despite the existence of guidelines for 
cancer care management, undertreatment is a widespread problem [37]. The quality of life of a 
cancer patient deteriorates when there are discrepancies in pain management. Poor pain 
assessment, difficulties in patient communication, inappropriate prescribing of drugs and doses, 
failure to adjust dosing intervals when necessary which are all factors contribute to 
undertreatment issues in palliative care [37].  
 
Deprescribing at the end stage of a patient’s life is a complex issue and often it is important for 
maintaining a patient’s quality of life [38]. Deprescribing could be considered when there is 
polypharmacy, adverse drug reactions, ineffective treatment, falls or when treatment goals have 
changed. It is prudent to consider deprescribing during the end of life care, when re-evaluation of 
a treatment goal is needed. Many preventive therapies such as medicines used to treat 
hypertension, osteoporosis and hyperlipidaemia will have limited value in patients reaching the 
terminal phase of an illness such as cancer [38]. Furthermore, the pharmacokinetics and 
pharmacodynamics of many medicines change during this stage and pose more harms than 
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benefits to the dying patient. Deprescribing will reduce the medicine load and potential adverse 
effects, while shifting the therapeutic focus to end-of-life issues that are important to the patient. 
 
As the world population continues to grow older, the need for palliative care service increases. 
The incorporation of preventive methods in palliative care service provision - such as patient and 
physician education, and regular medication list review and monitoring - prior to occurrence is 
critical to reach a balance between controlling symptoms and achieving comfort and quality of 
life 
 
1.4 Overview of palliative care services in North West Tasmania 
1.4.1 Palliative care services in North West Tasmania 
 
The North West region of Tasmania is characterised by low and dispersed settlement densities 
and is classified as a rural and remote region (Figure 4). The widely dispersed population spreads 
over an area of 22,202 square kilometres and has only two primary urban activity centres, Burnie 
and Devonport [39]. 
In terms of remoteness, which is measured by the Accessibility/Remoteness Index for Australia 
(ARIA), Tasmania has no centres of population of over 250,000 and is separated from the 
nearest metropolitan city, Melbourne by the Bass Strait [40, 41].  
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Figure 4. Structure of the Rural, Remote and Metropolitan Areas (RRMA) Classification [39]. 
Besides the remoteness, people living in this region tend to experience lower socio-economic 
conditions, and have relatively high rates of obesity, smoking, lack of exercise and high of 
alcohol consumption compared to people living in metropolitan areas [40].  
Tasmania has the oldest median age (40.8 years) of all Australian states and territories, and the 
highest proportion (17%) of people aged 65 years and over [42]. Statistically the North West 
population in this region has been ageing faster than any other area in Australia [43]. One of the 
most challenging issues facing health service delivery in Australia is the demographic reality of 
population ageing. An ageing population will lead to a growing dependency ratio in the region 
and the need for increased health service industries to meet the needs of the elderly. The burden 
of disease from an ageing population and increase chronic disease will potentially impact the 
North West Tasmanian community significantly. 
One such area is the provision of palliative care to aged persons in more remote locations and 
scattered towns and communities across the region. This has been identified as as a significant 
challenge by the North West palliative care team.  
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1.4.2 North West Tasmania palliative care setting  
The palliative care services/resources available in North West Tasmania are supported by The 
North West Tasmanian Department of Health and Human Services’ (DHHS) Palliative Care 
Service. They have identified the need to strengthen the partnerships and local palliative care 
networks particularly on the extension of inpatient palliative care facilities in the North West 
[44].  
The North West Palliative Care Service works with primary health and acute care services to 
improve and develop palliative care services. Primary palliative care is provided for patients 
across all health care settings. Primary care providers include all health services and staff that 
have a primary or first contact relationship with the patient with a life limiting illness.  
However, it is understood that most rural and remote communities are unlikely to receive the 
range of medical and health services characteristic of large urban centres. There is a need to 
develop primary health palliative care services supported by a general practitioner (GP) led 
workforce with sound palliative care knowledge and skills.  
Tasmania has 10 designated beds in the palliative care inpatient units in Hobart, 6 beds in 
Launceston, but no designated inpatient or hospice palliative beds in the North West of Tasmania 
[6]. The settings of care in North West Tasmania are therefore mostly community based, with the 
majority of patients being assessed and treated at their home or residential aged care home. 
Strengthening primary care and community support and improving safety and quality in 
alternative residential settings is an important goal for the DHHS. 
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1.4.3 Barriers and difficulties faced by North West palliative care service 
 
There are important challenges faced by the palliative care team in regional towns and 
rural/remote areas. These issues mainly related to the access of service, the coordination of 
palliative care, the maintenance to the interdisciplinary palliative care teams and sufficient bed 
allocation in acute hospitals [45]. On the other hand, population ageing also causes an increase 
demand for medical services and lead to many workforce-related issues [46].  
 
1.4.3.1 Access to palliative care service 
 
Access to health care for patients living in rural and remote areas of Australia has always been 
problematic.  The lack of accessibility to health professionals often turn out to be an impediment 
to good palliative care service particularly when after hour care is needed. Family members of a 
patient are facing various difficulties associated with the provision of care to a patient, especially 
at night. The lack of 24-hour palliative care coverage leads to a reliance on hospital emergency 
room services at night when care is urgently needed [45].  
 
In rural and remote Australia, the dispersed nature of the population incurs heavy cost burdens 
on both patients and health care services because of the distances they are required to travel to 
access and provide health care. For many patients, the vast distance with poor roads and lack of 
public transport also poses as common problem to get a proper healthcare support.  
 
For palliative care service providers, remoteness means difficulties in carrying out patient 
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assessments and symptom management resulting in uncertainties about how to resolve practical 
caregiving problems. Consequently, a reduced palliative care input and limited choices for home 
care may reduce the patients’ quality of life. 
 
1.4.3.2 Co-ordination of palliative care service and work force related issues 
 
The North West Tasmania’s dispersed population means that there is high demand of home 
medication review and telephone counselling for patients. However, healthcare workers have 
difficulties to provide adequate symptom management and assessment of the patient’s condition 
when these are assessed remotely [47].   
 
According to Walker, Behrens and Dow’s [47] survey, there is no actual multidisciplinary/ 
interdisciplinary practice in the North West Tasmania region of palliative care service.  
Information is loosely processed and there is impaired communication and conflicting views of 
the roles and responsibilities of the service providers. These have been identified by Walker and 
Behrens as key barriers to effective service delivery and working relationships between palliative 
care providers.  
 
As an interdisciplinary team approach is the aim of palliative care services, patient outcomes 
would improve when GPs and specialist palliative care teams communicate well and work 
together collaboratively, but Walker et al claimed that the local GP involvement in the North 
West region is often hard to obtain. They concluded that due to the geographical barriers, 
accompanied by the independent and autonomous nature of the role of rural and remote GPs, 
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these factors impede the quality coordinated palliative care delivery on North West Tasmania 
[47].  
 
Furthermore, the shortage of skilled health professionals who are willing to take part in the 
provision of palliative care is also a barrier to the provision of palliative care [48]. The current 
interdisciplinary team providing service in the North West region consists of a GP and four 
clinical nurse consultants. Recently, the North West palliative care service expanded its 
interdisciplinary team with the addition of an occupational therapist and a social worker. 
However, there is still a shortage of allied health professionals to look after the patients 
holistically. 
 
1.4.3.3 Difficulties in bed allocation 
 
Bed allocation during end of life is difficult in the North West with no designated beds for 
palliative care patients. According to the Centre for Health Service Development [6], the 
absences of designated beds for palliative care service in the North West is a result of the 
‘Hospice without walls’ model, which does not suggest a stand-alone hospice due to the disperse 
population. In this model, palliative bed designation was strongly encouraged but it was 
recommended that the beds be spread between, existing acute and rural hospitals [6]. As a 
consequence, palliative patients need to travel to access services and then face uncertainties 
regarding bed availability. 
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1.4.3.4 Geographical and demographic factors 
 
Distance and weather conditions are significant factors when individuals consider commuting for 
palliative care [45]. The cost and time commitments of travelling to urban centres (Hobart or 
Melbourne) for palliative care are burdens to overcome. Not only costs associated with health 
care delivery are increased, there is often lack of timely and sufficient palliative care service to 
rural patients available to rural palliative care patients related to insufficient numbers of 
providers. Furthermore, patients’ emotional state can be affected due to the needs to travel to 
unfamiliar environment.  
 
1.4.3.5 Patient Awareness factor 
 
Patients living in remote regions are often not aware of the availability of palliative care services 
[48]. Information about their illnesses are also lacking due to reduced health care provider input 
and limited choices for home care. There are other disadvantages and barriers faced by these 
rural patients, factors such as lower education status, reluctant to use palliative service because 
patients, family members equate palliative services to death. 
 
1.5 The role of pharmacist in palliative care 
Since the goal of palliative care is largely depended on symptom management with significant 
reliance on medication management, pharmacist involvement in an interdisciplinary team is 
potentially beneficial. This is why there are an increasing number of health professionals and 
researchers believe pharmacists should be an essential aspect of an effective interdisciplinary 
	22	
team [49, 50, 51]. 
 
1.5.1 Traditional role of the pharmacist 
 
Traditionally, the role of a pharmacist includes compounding and dispensing medications safely 
and effectively. The pharmacist’s expertise is the knowledge and information in drugs, 
medication devices, and patient counselling. Their easy accessibility to the public also makes 
them a quick reference for medication use [49]. The traditional pharmacist’s main focus was 
product management, more of a product and task oriented (dispensing) role [50] and they were 
not usually identified as a vital member of the healthcare team. 
 
1.5.2 Expanded role of the pharmacist  
 
In palliative care, the concept of pharmaceutical role has expanded the pharmacist roles into a 
new dimension. Hepler and Strand [50] define pharmaceutical care as the “direct responsible 
provision of drug therapy for the purpose of achieving definite outcomes and improve a patient’s 
quality of life” (Page 539). This statement shows the similarity of pharmaceutical care to the core 
principle of palliative care. Both emphasise the patient’s quality of life as the eventual outcome, 
and both stress the holistic aspect of healthcare. This is also supported by the American Society 
of Health-System Pharmacists (ASHP). ASHP claims the goal of palliative care and 
pharmaceutical care is consistent and pharmaceutical care is a necessary component of good 
palliative care [49]. The aim of pharmaceutical care is not only to improve a patient’s comfort; it 
can also be applied to cure a disease, to eliminate or reduce of patients’ symptoms, to slow down 
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a disease process or prevent a disease. The ASHP believes the pharmacist has a pivotal and 
multifaceted role in the provision of hospice and palliative care [49]. ASHP claimed that high-
quality hospice and palliative care requires both traditional and expanded pharmacist activities.  
 
With these aspects, the pharmacist’s position in palliative care would be transformed to a patient-
oriented profession, with emphasis on the provision of care, particularly in medication advice 
and counselling [11,12].  
 
According to the the ASHP, the expanded role of pharmacist includes [49]: 
1. Assessing the appropriateness of medication orders and ensuring effective medications for 
symptom control.  
2. Counseling and educating the palliative care team about medication therapy.  
3. Ensuring that patients and caregivers understand and follow the directions provided with 
medications.  
4. Providing efficient mechanisms for extemporaneous compounding of nonstandard dosage 
forms.  
5. Addressing patients’ financial concerns about palliative medications.  
6. Ensuring safe and legal disposal of all medications after death.  
7. Ensure patients’ compliance with laws and regulations pertaining to medications. 
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1.5.2.1 Medication management and review 
 
Peter Gilbar [51] in his survey claimed that medication review was the most common clinical 
duty of a pharmacist in an interdisciplinary team. When a pharmacist plays a proactive role in 
performing medication reviews, pharmacotherapy for patients is improved [52].  By interacting 
with health providers in the team, the pharmacist can be actively involved in patient rounds, 
interviewing patients, assessing the appropriateness of medication orders and ensuring the timely 
provision of effective medications for symptom control. Pharmacists also maintain patient 
medication profiles and monitor all prescription and non-prescription medications use for safety 
and effectiveness [49]. Furthermore, they can provide patients discharge counselling and follow 
up.  
 
It is even more important for the pharmacist to play a vital role when the condition of a patient 
declines and enters into the terminal stage of illness.  At this stage, the need to evaluate 
interventions based on short-term symptom management goals is imperative. Pharmacists can aid 
the interdisciplinary team in deciding how and when to taper and discontinue medications to 
simplify the patient’s profile, reducing pill burden, decreasing the risk of drug interactions, and 
easing medication administration by family/carers [53]. 
 
In developed countries, elderly populations have a particularly high incidence of medication 
misadventure, accounting for up to 14 to 30% of all hospital admissions. Medication 
misadventure not only decrease quality of life but presents a burden on the health care system. 
Non-compliance is a major contributor to this problem, accounting for 21 to 59 per cent of 
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medication related admissions in the elderly [54]. 
 
A complete and accurate medication history is crucial to avoid future medication misadventure. 
The pharmacist is ideally qualified to do medication review and checking histories as they have 
specialised knowledge of medications. Studies have already demonstrated that pharmacists are 
best suited to carry out this important role in patient care [55, 56]. The presence of a pharmacist 
has been shown to decrease preventable adverse drug reactions as pharmacists help intercept 
errors as well as to recognise ongoing medication related problems [34].  
 
1.5.2.2 Symptom and pain management 
 
Gilbar [51] in his survey has claimed that pharmacists are capable of providing specific advice 
on pharmacotherapy, administration, treatment, adverse effects and incompatibilities in 
collaboration with other health disciplines. Since the majority of palliative care patients 
experience chronic pain, pain management has received the most attention in palliative care [57]. 
Gagnon [57] who looked at the contribution of pharmacists retrospectively in a Rapid access 
palliative Radiotherapy program (RAPRP) found that pharmacists can play a pivotal role in 
improving symptoms by optimising medication regimens, enhancing adherence through patient 
education and prevention of side effects, collaboration with other health providers, monitoring 
outcomes and conducting research. Gagnon claimed that the success of this program is a holistic 
patient approach, in which the pharmacist plays a significant role. 
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This is a broad area for the pharmacists to provide drug therapy and dispensing controlled drugs 
for patients in palliative care. Pain management such as opioid rotation and equianalgesic 
conversion calculations could be performed by the pharmacists to support and advise physicians 
[58]. For instance in the situation when there is morphine administration in the elderly and in 
patients’ with renal dysfunction [59], pharmacists can support physicians in preventing opioid 
over-dosage in patients with renal failure.  
For symptoms management besides pain, the pharmacist role is to improve symptoms by 
optimizing medication regimens, enhancing adherence through education of the patients and 
their family members.  
 
When a pharmacist was included in a palliative care multidisciplinary team, Hussainy et al [34] 
recorded an increase in confidence of patients/carers in the use of medications and medication 
errors by both health professionals and patients/carers were reduced. Hussainy et al stated further 
stated that by incorporating a pharmacist in a multidisciplinary team, this would lead to an 
improved symptom and pain management, and therefore, a reduce hospital readmission. 
 
This role of pharmacists has been recognised in different palliative care practice settings by 
different researchers. In hospice setting, the role of the pharmacist continues to expand. Clinical 
pharmacists working in hospice organisations were getting recognised by other healthcare 
professionals as core members of multidisciplinary teams [60]. There were also studies and 
recommendations about the benefits of community pharmacists being involved in palliative care 
team approach [61, 62].  
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Pharmacists play a pivotal role in improving quality use of medicines. Their expertise is needed 
to perform Home medicines review/Residential Medication Management Review 
(HMR/RMMR). A HMR/RMMR service is a comprehensive medication review performed by an 
accredited pharmacist [63]. By systematic evaluation of the patient’s complete medication 
regimen and management of that medicine, pharmacists can improve therapeutic outcomes for 
the patients and ensure appropriate, safe and effective use of medicines [63] 
 
1.5.2.3 Collaboration with other health providers  
 
The pharmacist is also capable of acting as a drug knowledge resource for the interdisciplinary 
team. This collaboration with other health providers may lead to better clinical outcomes to 
improve the patients’ comfort and quality of life. During regular interdisciplinary meetings, 
pharmacists can advise other team members about medication therapy. This may include advice 
on dosage forms, routes of administration, costs, and availability of various drug products. 
Another important area in which the pharmacist can contribute their knowledge is the prevention 
of drug toxicity from drug-drug interactions and also with dietary supplements and other 
alternative/complementary therapies [49]. Spinewine et al [64] suggested the pharmacists should 
be integral members of all hospice interdisciplinary teams because their involvement will result 
in the most cost-effective therapies with fewer side effects and reduced potential for drug 
interactions. In other words, positive outcomes related to drug medications are achieved when 
the pharmacist collaborates closely with other health care professionals [52].  
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1.5.2.4 Patient counselling and education 
 
While assessing the patient for adverse drug reactions during drug therapy, the pharmacist can 
provide counselling and education to the patients and their carers by carefully explaining dosage 
regimens and discussing potential side effects of medications with them [49]. Important issues, 
especially during pain management, such as the misconceptions about addiction to opioids, drug 
dependence and toxicity can be explained. The pharmacist can also ensure that all medication 
labelling is complete and understandable by patients and their carers in order to encourage drug 
adherence. Additional roles and responsibilities include ensuring safe and legal disposal of all 
medications after death, finding alternative generic medicines to address the financial problems 
of the patients, and also making sure there is adequate stock and continuous supply of 
medications for the treatment of the patients. 
 
1.6 Conclusion 
 
North West Tasmania is a vast and remote region with an ageing population. Since elderly 
people are prone to cancers and chronic diseases and drug-related problems (DRPs) are  
commonly experienced by patients receiving palliative care. the need for healthcare services in 
rural and remote communities is undoubtedly high, especially in the area of palliative care. It has 
been reported that access to optimal healthcare for rural and remote area patients has been 
problematic and many are receiving suboptimal palliative care services. For instance, home 
medication review/residential medication review (HMR/RMMR) is common in metropolitan 
area, but in regional/ rural Tasmania, it is rarely implemented due to the vast geographical 
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location and dispersed population.Thus, an efficient and quality assured standard of palliative 
care service is needed.  
 
With the barriers faced by the North West palliative care service and rural patients, it seems the 
involvement of a pharmacist in the provision of community based palliative care service would 
be appropriate to alleviate the above challenges and supporting the palliative care patients in 
their respective communities.  
 
The North West Tasmanian region needs a high quality and coordinated palliative care services 
with an increase collaboration and knowledge among the dispersed rural palliative care 
providers. By including a pharmacist in the community-based palliative care setting, it gives an 
‘added value’ to the current workforce to prevent medication misadventure and symptom 
management. The pharmacist has a well-defined and important role in palliative care to alleviate 
patients’ drug related problems by participating in an interdisciplinary team. Consequently, we 
postulated that the inclusion of a pharmacist could be beneficial for palliative care services in 
North West Tasmania.  
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2 Aims 
 
The main aim of this study was to explore the potential for pharmacist participation in 
community-based palliative care services in North West Tasmania. The specific aims were to 
investigate the nature and extent of DRPs in palliative care patients in North West Tasmania, to 
explore North West palliative care providers’ views on the potential advantages of pharmacist 
involvement in their team, and identify any barriers to this inclusion. 
 
 
3 Methodology 
 
The study was conducted in two stages. 
 (1) A retrospective audit to collect the palliative care patients’ data for DRP assessment.  
(2) A focus group discussion to explore the views of North West palliative care team members 
on DRP management during their community-based practice. 
 
3.1 Retrospective audit of palliative care patient medication records  
3.1.1 Study Design 
 
In this study we retrospectively examined and identified DRPs from the North West palliative 
care home-based patients’ medication records. The researcher collected relevant patient 
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information, including demographics, medications, medical history and relevant laboratory data 
to investigate their impact on patient outcomes. 
 
In this study, the first three encounters of the palliative patients recorded by the palliative team 
were reviewed. Their clinical assessments and medication managements of the patients were 
categorised and screened for DRPs.  
 
For DRP assessment, we first identified the symptoms as written in the medical notes, then DRPs 
were categorised using the D.O.C.U.M.E.N.T classification system [65] and their possible causes 
determined. The data were later analysed using SPSS version 22 for Mac. A descriptive analysis 
was undertaken. 
 
3.1.2 Patient selection 
 
This study focused on the North West Tasmanian community setting managed by the North West 
Palliative Care team. Cancer patients were identified as the target population and their medical 
records were reviewed retrospectively. The medical records (from August 2012 to August 2013) 
were collected from the patient archives that were retained in the North West Palliative care 
office, at Parkside, Burnie. Access to data from the medical records were done under the 
supervision of GP and nurse in charge. 
 
The patient records targeted for this study were those who were referred to the palliative care 
teams by health professionals from the community or institutions. The patients were home-
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dwelling with their family members and/or carers. Those who were receiving palliative care 
services in residential care facilities were also considered as eligible patients for this study.  
 
The exclusion criteria for the sample selection were:  
1) Patients who were treated by another palliative care team for their terminal illnesses;  
2) Patients not living at home or supported residential facilities; or  
3) No/Incomplete patient profile/medication notes recorded by the palliative care team.  
 
3.1.3 Data collection and data entry 
 
 One-hundred patients’ medical records were retrospectively reviewed and documented for 
analysis by the research pharmacist. The patient names and contacts were not recorded. A unique 
identifying code was assigned to each patient and the data stored using this code. Since the study 
focused on the medical archives review of the patients, the informed consent was not required in 
this study as it did not require any contact with or direct participation from the patient 
themselves. 
 
3.1.3.1 Patient characteristics 
 
Before carrying out the retrospective study, a data collection sheet (Appendix 1) was developed 
to record the patients’ demographics (age, gender, types of cancer, patient living days). The 
medical conditions of the targeted cancer patients prior to their first palliative care service were 
recorded with reference to the North West Client registration form. The above mentioned 
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patients’ demographic and clinical characteristics provided reason for admission and also acted 
as baseline assessments. Other patient-related factors such as chronic liver disease, renal 
impairment and comorbidities were useful to identify any patient-related factors that might 
potentially contribute to DRPs. For each of the palliative care services received by the patients, 
comorbid conditions were recorded from their medical history notes. 
 
3.1.3.2. Medication record 
 
A data collection sheet was designed to record medications (Appendix 2) prescribed to the 
patients during their first three encounters of the palliative care. The data sheet was used to 
document the type of medications, the name of drugs, their dosage frequency and changes to the 
drug managements commenced by the palliative care team. The medication records from each 
visit by the palliative care team were recorded and labelled as ‘On Admission’, ‘Contact 1’ and 
‘Contact 2’ for each assessment by the palliative care team.  
 
These data were reviewed to identify any medication regimen changes or modifications due to 
DRPs, other medication-related issues such as polypharmacy, under-treatment of symptoms, 
adverse drug reactions and patient non-adherence were also recorded. 
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3.1.3.3. DRP Assessment  
 
In the DRP assessment sheet (Appendix 3) the researcher would first describe the symptoms as 
written in the medical notes, then the DRPs and their possible causes were identified and 
categorised using the D.O.C.U.M.E.N.T classification system [65].  
 
The system consisted of eight categories (types) of DRP. Each category was further classified 
and encompassed with several subcategories (Appendix 4). The types of DRP classified in the 
D.O.C.U.M.E.N.T system were defined as follows: 
 
• Drug selection—DRPs related to the choice of medications prescribed by community GP or 
palliative care doctor. A regimen that implied too frequent or too infrequent dosing, multiple 
drugs, or both may be too complicated for the patients to follow. It also included OTC products 
that the patients purchased for symptom relief. Subcategories: drug duplication, drug interaction, 
wrong drug and no apparent indication. 
• Over or underdose prescribed—DRPs related to the prescribed dose or schedule of the drug. 
Generally, in palliative care dosage needed to be monitored closely, especially when the patients 
were elderly. Subcategories: dose too high, dose too low and incorrect schedule. 
• Compliance—DRPs related to the patient’s medication- related behaviour.  Most commonly, it 
referred to medication or drug compliance. It was used to describe whether a patient correctly 
follows medical advice Subcategories: taking too little, taking too much, intentional drug misuse 
and difficulty using a dosage form. 
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• Untreated indications—DRPs related to actual or potential conditions that require interventions 
or management. Subcategories: a diagnosed condition not adequately treated or preventative 
therapy required. 
• Monitoring—DRPs related to inadequate monitoring of the efficacy or adverse effects of a 
drug. This applied when a medical problem was being treated with the correct drug, but the 
patient is not adequately monitored for complications, effectiveness, or both. Subcategories: 
laboratory and non-laboratory monitoring. 
• Education or information—DRPs related to knowledge of the disease or its management. It 
applied to the education and counselling given to the patients and their carers, at the same times, 
it also applied to education acquire or update by the team members. Categories:  requests for 
drug information, confusion about therapy or disease states and demonstration of dose 
administration devices. 
• Non-clinical—DRPs related to administrative aspects of the prescription. 
• Toxicity or adverse reaction—DRPs related to the presence of signs or symptoms which were 
suspected to be related to an adverse effect of the drug. Categories: toxicity caused by dose, drug 
interaction or unknown causes. 
Appendix 4 shows the different categories of the D.O.C.U.M.E.N.T classification and our own 
version of D.O.C.U.M.E.N.T table used to classify patient DRPs. 
 
3.1.4 Statistical analysis 
 
Data were analysed using SPSS statistical software Version 22 for Mac. The study statistics were 
predominately descriptive.  Binary outcome variables (yes/no) were recorded for the presence of 
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DRPs.  The associations between independent variables (age, gender, types of symptoms, types 
of medications) were conducted using chi-squared analysis.  A p-value of <0.05 was considered 
statistically significant. 
 
 
3.2 Focus group discussion with North West palliative care services providers 
3.2.1 Focus Group 
 
In our second study, we organised a focus group discussion to explore the palliative care team 
members’ views on the DRPs encountered and their approach to DRP management during their 
community-based practice. We also aimed to explore their views on the potential advantages of 
pharmacist involvement in their team and identify any barriers for this inclusion. 
 
According to Hansen [66], through interactive discussions and sharing experiences, opinions and 
views, focus groups let people spark off each other and bring new dimension to the topics. Focus 
groups also allow researchers to use their own frames of reference and to identify the topics that 
were important to them. They enable each participant to raise new issues and gain a better 
understanding of the reasons behind people’s action and opinions. 
 
It was hoped that through the focus group discussion, shared experience from the participants 
would help to identify different issues and challenges faced by the North West palliative care 
service providers, patients and carers.  
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3.2.2 Recruitment and participants 
 
We recruited 12 participants from the North West palliative team. There were made up of two 
palliative doctors, a chief nurse, one nurse consultant, five nurses, two allied health workers and 
a temporary palliative care pharmacist. The participants were informed a month earlier by email, 
and later they were reminded verbally by the palliative care doctor about the focus group 
discussion to make sure they were aware of the meeting date.  
 
Each participant received a letter of invitation, an information sheet (Appendix 5), a letter of 
consent (Appendix 6) and the question guides (Appendix 7) from the researchers before the 
meeting date. 
 
The 12 participants were willing to take an hour off their working afternoon to attend the focus 
group.  The focus group were held in the North West palliative care conference room to avoid 
being disturbed and they felt at ease in the room where they were having weekly clinical 
reviews. 
 
The issue of participants being ‘not representative’ was minimal, since the whole North West 
palliative team were invited to take part in this focus group discussion. One of the doctors acted 
as the group facilitator who introduced the topics for discussion and moderated the group. His 
role was to maximise interactions between the focus group participants to interaction and 
contribute ideas in a lively and natural discussion amongst themselves. The facilitator was also 
able to contribute his viewpoints throughout the discussion 
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3.2.3 Data collection  
 
Questions were asked in a group setting where participants were free to talk with other group 
members. Through interactive discussion, the experiences, opinions and views of each 
participant were recorded by audio devices and later transcript for qualitative analysis. The audio 
file was sent to SmartDocs Transcription Service to transcribe into text data. The transcription 
was later analysed together with the audio recording using qualitative thematic analysis. 
Since we wanted to seek people’s experiences and opinions in order to answer our research 
questions, thematic analysis was deemed to be ideal to identifying important themes and 
patterned meaning from our data.  
 
The focus group meeting was expected to last for approximately 60 minutes. Each participant 
was assigned a number as a unique identifier. We developed a question guide (Appendix 7) to 
address our aims and the three main areas that we would like to explore. The questions presented 
to the focus group were designed as open-ended questions as these would encourage the 
participants to have great freedom to provide information. Primary questions introduced new 
topics and secondary questions were asked to seek clarification. The participants were also 
encouraged to raise their own issues and freely shared their views on the topics concerned. 
 
Thematic analysis is widely used in the field of qualitative health research to explore people’s 
experiences, views and perceptions. Themes and patterns from a group of data [66, 67] were 
identified in order to answer research questions. A theme is defined as a recurring issue that 
emerged during the analysis of qualitative data [66].  
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In order to perform thematic analysis, the researchers need to used a coding system to count the 
number of times a particular theme/opinions/keywords is expressed [68]. Themes were recorded, 
reviewed for common patterns for result interpretation.  
 
 
3.3 Ethics 
Approval was granted by the Tasmanian Health and Medical Human Research Ethics Committee 
(REF: H0013775 and H0015369). 
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4 Results 
 
4.1 Retrospective study of palliative care patient medication records  
4.1.1 Patient demographics 
 
One-hundred of the admitted palliative patients were randomly selected on admission to the 
North West Tasmanian Palliative Care Team as a convenience sample for our retrospective audit  
using a random number generator (Figure 5). All 100 participants had a primary diagnosis of 
cancer. During the data collection, the patient numbers in first contact of palliative care (C1) and 
the second (C2) dropped to 99 and 76 respectively, due to patient deaths.  
 
 
 
 
 
 
 
Figure 5. Patients’ first three contacts with palliative care team flow chart 
 
 
 
A summary of the patient demographics and clinical characteristics is provided in Table 1. 
 
 
Palliative	care	
patients	on	admission	
(OA)	
	
(n=100)	
Palliative	care	patients	
on	contact	1	(C1)	–	first	
assessment	by	palliative	
care	team	
	
(n=	99)	
Palliative	care	
patients	on	contact	2		
(C2)	–	second	
assessment	by	
palliative	care	team	
	
(n=	76)	
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Age 
 
Median 
 
Range 
 
68 
 
 
 
15-95 
Gender n (%) Male Female 
67 (67) 33 (33) 
Cancer type n (%)
  
Bone & skin  
9 (9) 
 Lung  
27 (27) 
Brain  
5 (5) 
Urogenital  
21 (21) 
Breast  
4 (4) 
Endocrine  
15 (15) 
GIT  
8 (8) 
Blood and 
adenocarcinoma 
 
11 (11) 
Days of life n (%) 1 month or less  
29 (29) 
> 1 month  
71 (71) 
Patients with 
impairments n (%) 
Liver  
55 (55) 
Kidney  
44 (44) 
Documented co-
morbidities n 
(%)
  
1  
33 (33) 
2  
9 (9) 
>2  
7 (7) 
 
 
Table 2. Patient demographics on admission 
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Approximately two-thirds (n=67) of the patients were male and the most prevalent cancer was 
lung cancer, followed by urogenital and endocrine cancers. With regards to palliative care, 71 
patients lived longer than 30 days under the care of the North West palliative team. Over half of 
the patients (55%) treated were documented as having liver impairment and 44% of patients 
were recorded with kidney failure. One third (33%) of patients required treatment for a type of 
chronic disease by the time of admission.  
 
 
4.1.2 Drug related problem frequencies 
 
Table 3 shows the frequencies of drug related problems (DRPs) at each contact. Fifty-two 
percent of the sample experienced one or more DRPs on admission to the palliative care service.  
The percentage of DRP occurrence increased slightly to 56.6% during C1 then decreased to 50% 
(C2). The lowest number of DRP recorded for the patient was 1 at every encounter, and the 
highest were 8 (OA), 7 (C1) and 10 (C2). There was a decrease of the median of DRP from 5 to 
4 when the palliative care team intervened. The median of the DRPs were 4 for both C1 and C2. 
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 OA 
N=100 
 
C1 
N=99 
 
C2 
N=76 
 
Number of patients with DRPs n (%) 
 
52 (52) 56 (56.6) 38 (50.0) 
Range of DRP 
 
7 6 9 
Lowest number of DRP 
 
1 1 1 
Highest Number of DRP 
 
8 7 10 
Median 
 
5 4 4 
OA=On admission 
C1=First contact of the patient 
C2=Second contact of the patient 
 
Table 3. The proportion of patients with DRPs at each contact 
 
We further categorised the different DRPs using the D.O.C.U.M.E.N.T classification as shown in 
Table 4. Prior to admission, T (Drug toxicity) was the most frequently reported issues, followed 
by drug selection problems (D), patient noncompliance (C) and over/under dosage problems (O).  
 
After the first palliative care contact (Table 4), the most reported problem was again drug 
toxicity (T), which were mainly due to medication adverse effects. This was followed by patient 
compliance issues (C), drug selection problems (D) and sub-optimal patient knowledge of their 
medications (E).  
 
At C2 (Table 4), drug toxicity and side effects were still the major issues (24% of the patients) 
faced by the palliative care team, followed by drug selections and dosage problems. Compliance 
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issues showed the biggest improvement when patients were receiving palliative care, with the 
reported proportion of compliance-related DRPs reducing from 18% to 9%. However, adverse 
effects, drug selection and dosage problems did not reduce after the two palliative care contacts. 
 
 
 DRP_OA 
(n=100) 
n (%) 
DRP_C1 
(n=99) 
n (%) 
DRP_C2 
(n=76) 
n (%) 
D 20 (20.0) 18 (18.2) 14 (18.4) 
O 12 (12.0) 13 (13.1) 14 (18.4) 
C 18 (18.0) 20 (20.2) 7 (9.0) 
U 7 (7.0) 13 (13.1) 7 (9.0) 
M 6 (6.0) 9 (9.0) 8 (11.0) 
E 2 (2.0) 15 (15.2) 3 (4.0) 
N 3 (3.0) 5 (5.0) 3 (4.0) 
T 21 (21.0) 23 (23.2) 18 (24.0) 
 
Table 4. DOCUMENT system frequencies at each contact 
 
 
4.1.3 Patient characteristics vs DRPs 
 
Chi-squared analyses were performed to compare patient characteristics and DRP frequencies is 
shown in Table 5. There was a statistically significant increase in DRP occurrence in patients 
with hepatic impairment at the first encounter of palliative care (P =0.03).  Beside hepatic 
impairment, no other patient characteristics showed any statistically significant associations with 
DRPs. 
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     Patient 
Characteristics 
 
 
DRP_OA 
(N =100) 
 
n (%) 
DRP_C1 
(N = 99) 
 
n (%) 
DRP_C2 
(N =76) 
 
n (%) 
DRP 
Anytime 
 
n (%) 
              P Value 
OA C1 C2 Anytime 
Gender  
 
M 
(n=67) 
F 
(n=33) 
34 (50.7) 
 
18 (54.5) 
56 (57.6) 
 
18 (54.5) 
25 (49.0) 
 
13 (54.2) 
24 (72.7) 
 
49 (73.1) 
0.721 0.774 0.677 0.966 
Liver 
Impairment 
 
Yes 
(n=55) 
26 (47.3) 28 (50.9) 21 (48.8) 16 (84.2) 
 
0.232 0.033 0.172 0.201 
Kidney  
Impairment 
 
Yes 
(n=44) 
23 (52.3) 22 (51.2) 17 (50) 38 (69.1) 0.642 0.210 0.554 0.893 
CoM =1 
 
Yes 
(n=33) 
14 (42.4) 18 (56.3) 14 (56) 22 (66.7) 0.170 0.703 0.410 0.239 
CoM=2 
 
Yes 
(n=9) 
4 (44.4) 6 (66.7) 2 (25) 6 (66.7) 0.630 0.621 0.145 0.601 
CoM>2 Yes 
(n=7) 
5 (71.4) 6 (85.7) 3 (60) 6 (85.7) 0.287 0.135 0.620 0.462 
 
OA = On Admission, C1 = Contact 1, C2 = Contact 2, 
 
DRP Anytime = A combined DRP occurrence from OA, C1 and C2 
 
CoM = Comorbidities 
 
 
 
Table 5. Patient characteristics vs DRPs 
 
4.1.4 Symptom Management and DRPs 
 
Table 6 shows the frequencies of symptoms experienced by the patients at each contact recorded 
by the palliative care team. Fatigue was the most prevalent symptom at each contact. There were 
statistically significant differences over time for fatigue, pain, shortness of breath, constipation, 
nausea/vomiting, appetite problems, restlessness/anxiety and insomnia. 
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Table 6. Number of patients with Symptoms and time cross-tabulation (rates of symptoms) 
 
On admission, there were 93 patients showing signs of fatigue. This was followed by appetite 
problems as the next most commonly reported symptom, which existed among 75% of patients. 
Sixty-nine patients (69%) were admitted with pain issues, and there were 68 suffered 
constipation (68%).  At least half of the patients reviewed had dyspnoea, nausea/vomiting and 
insomnia issues. 
 
Symptoms OA 
(N=100) 
n (%) 
C1  
(N=99) 
n (% ) 
C2 
(N=76)  
n ( %) 
P Value 
Pain 69 (69.0) 57 (57.6) 36 (47.4) 0.015 
Shortness of Breath 61 (61.0) 42 (42.4) 27 (35.5) 0.002 
Constipation 68 (68.0) 48 (48.5) 30 (39.5) 0.001 
Nausea/Vomiting 51 (51.0 ) 43 (43.4 ) 18 (23.7) 0.001 
Fatigue 93 (93.0 ) 72 (72.7 ) 48 (63.2) 0.001 
Appetite problems 75 (75.0 ) 48 (48.5 ) 38 (50 ) 0.001 
Restlessness/Anxiety 3 (3.0 ) 14 (14.1 ) 7 (9.2 ) 0.020 
Insomnia 50 (50.0 ) 29 (29.3 ) 22 (28.9) 0.003 
Confusion/Hallucination 3 (3.0 ) 8 (8.1 ) 6 (7.9 ) 0.253 
Difficult Swallowing 3 (3.0 ) 7 (7.1 ) 5 (6.6 ) 0.395 
Weight Loss 5 (5.0 ) 4 (4.0 ) 1 (1.3 ) 0.418 
Delirium 5 (5.0 ) 3 (3.0 ) 3 (3.9 ) 0.777 
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During contact 1, symptoms of fatigue had been reduced to 72.7%. This indicated that the 
palliative care team started to make progress, and there was improvement of the patients’ quality 
of life. However, at this stage, 58% of the patients still complained about pain. During palliative 
care, these patients were treated by morphine and other opioids derivatives for their pain relief, 
the results showed that the occurrence of pain had been further decreased to 47% after the second 
palliative care contact (C2).  
 
The two opioid-related symptoms, shortness of breath and constipation, also improved over time. 
Restlessness and anxiety was also more frequently reported (14.1%) when the palliative care 
started at C1, but subsequently reduced to 9.2% during the second contact. 
 
We also found that symptoms like insomnia, delirium and weight loss were reported with less 
frequency after the commencement of palliative care (C1 and C2).  There were successfully 
reduced, but other symptoms like confusion/hallucination, and difficult in swallowing produced 
a different trend, as their occurrence increased when the patients first received palliative care 
(C1), with patients showing signs of improvement after C2. 
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4.1.5 Medication management vs DRPs  
 
With regard to the patient medications prescribed and recorded on admission and during 
subsequent palliative care contacts,  the prevalence of DRPs reported by nurses at each contact 
were recorded (Appendix 8). Table 7 shows the list of palliative drugs which showed a 
significant association with the prevalence of DRPs for each contact. 
 
The drug regimens often contained a combination of opioid and non-opioid analgesics, 
benzodiazepines, anti-nausea agents and laxatives. We categorised the palliative drug 
administration into three types:  
 
1) R = Regular dose,  
2) PRN = Dose administered only when necessary, and  
3) Any = Any form of dose administration, i.e either R or PRN, and sometimes both. 
 
From our data, the usage of morphine administered in regular dose (R) increased from 14 
patients to 30 patients after palliative care commenced. Midazolam (R) and haloperidol (R), 
which were often administered together with morphine during palliative care, also increased in 
usage by the palliative care team. We noticed that the usage of any form of benzodiazepines and 
haloperidol increased markedly when palliative care started. 
 
Our findings also showed that medications that were significantly associated with DRPs on 
admission to the palliative care service included paracetamol (PRN), oxycodone (regular or 
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PRN), hydromorphone (R, regular or PRN, clonazepam (R, regular or PRN) and metoclopramide 
(PRN). Fentanyl was significantly associated with DRPs when it was administered at regular 
doses and in any form of administration at C1 (P=0.019). Similarly, oxycodone (PRN) and 
haloperidol (R, regular or PRN) at C1 were also significantly associated with DRPs. At C2, when 
midazolam and haloperidol were both administered in regular dose and in any method to the 
patients, there was a significant association between these two medications and DRPS. 
 
Type of Drugs Medication Method Stages P Values 
Analgesic Paracetamol PRN OA 0.045 
Opioid Oxycodone PRN C1 0.015 
Opioid Oxycodone Any method OA 0.026 
Opioid Hydromorphone R OA 0.032 
Opioid Hydromorphone Any method OA 0.032 
Opioid Fentanyl R C1 0.019 
Opioid Fentanyl Any method C1 0.019 
Benzodiazepine Midazolam R C2 0.027 
Benzodiazepine Midazolam Any method OA 0.061 
Benzodiazepine Clonazepam R OA 0.028 
Benzodiazepine Clonazepam Any method OA 0.015 
Antinausea Haloperidol R C1 0.008 
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Antinausea Haloperidol R C2 0.049 
Antinausea Haloperidol Any Method C1 0.030 
Antinausea Haloperidol Any Method C2 0.025 
Antinausea Metoclopramide PRN OA 0.020 
 
Table 7. List of palliative drugs which showed a significant association with the prevalence of DRPs for each 
contact 
 
 
4.2 Focus group discussion 
4.2.1. DRPs encountered by the North West palliative care team 
 
A number of issues and concerns were raised by the palliative care team when discussing the 
occurrence of DRPs during their practice. These concerns are outlined below. 
 
(1) Inappropriate dosages given to the cancer patients were constantly an issue for the team to 
deal with. Drug labelling instructions and advice were often not followed by the patients and 
their family members. One palliative nurse explained: 
“There’s a resistance to change to medications, they (clients) actually like some of the things 
they are taking so they will have resistance.  Or there can be phobias about some of the 
medications when they might benefit, like opioids, morphine type drugs, they will have a phobia 
about those.  So we’ve got resistance and we’ve got phobias, so they’ll just suffer.”  
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(2) The geographical disadvantage was identified as a significant obstacle in palliative care 
delivery, which resulted in a shortage and irregular supply of palliative medicine to home-based 
cancer patients. This usually occurred in an aged care institution and drug supply problems also 
resulted in patients being undertreated. The nurse stated: 
 
“I’m just thinking about clients in aged care facilities and I reckon the thing I hear most from 
them is how much they have to wait for their medication, and they suffer quite a lot before they 
can be attended to.  And I understand that’s a resourcing issue, but it’s a big fear of people when 
they get put in aged care facilities.  And they suffer.” 
 
(3) The low socio economic status in North West Tasmania has resulted in some community GPs 
and palliative nurses being reluctant to keep patients’ medications well stocked at home for the 
fear of drug abuse by patients’ family members. Several participants had stressed this was noted 
as a concern for clients who were living in a ‘high social drug dependent community’.  
 
“We have a high social drug dependent community which is making our job very challenging, 
when we are trying to work out appropriate medication doses and safety issues in houses.  And 
the effects of those, we don’t know what we are dealing with.” 
 
(4) The community GPs prescribing habits also had a significant impact on the patient’s health 
outcomes. One nurse mentioned that communication between the community-based palliative 
care team and patients’ GPs was crucial for adequate drug supply in times of emergency since 
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most patients were required to see GPs whenever they ran out of drug supply. The nurse further 
stated that:  
 
 “The GPs won’t always give authorities so they (clients) are expected to go back to the GPs 
constantly, because they don’t have enough drugs in the house.” 
 
(5) The presence of a high turnover of medical practitioners and health professionals as locums 
often complicated the situation, with different professional views on the treatment of patients. 
Patients were required to adapt to different palliative approaches based on the multicultural 
background of healthcare professionals. This situation not only hindered the provision of an 
effective palliative care outcome but also left the allied health workers and patients in confusion 
each time they received different or contradicting advises from the health professionals. The 
nurse consultant further explained: 
 
“We have a multicultural lot of medical practitioners and other health professionals; they don’t 
always hear or understand what's being said.  So they can go on their senses to understand their 
medications.” 
 
The high turnover of GPs also contributed to many medication-related issues. Patients would 
often see different GPs regarding their treatment and medications. Sometimes patients were 
confused by the different information and advice provided by different GPs. The chief palliative 
care nurse stated: 
 
	53	
“One of the problems that I’ve observed over a long period of time is that some GPs are not 
prepared to rationalise a palliative care client’s drugs, at appropriate times. And that increases 
the burden for clients and their families.”  
 
(6) Low health literacy was also of concern. Some patients had difficulties reading and 
understanding different medication labels. Drug education and advice were scarce for patients 
and their carers. Palliative care service providers spent little time reviewing patients’ medication 
regimens due to the geographical challenges. The lack of drug education and medication 
information to the home-based cancer patients was thought to enhance the prevalence of DRPs 
experienced by the North West palliative care patients. One of the palliative care nurses said: 
 
“I think that our low level health literacy problems, people just don’t understand the drugs 
they’re taking. GPs not reviewing the drugs required for our clients. ” 
 
(7) The consumption of complementary and herbal medicine, some from overseas, was common 
practice among the patients. The palliative care nurses expressed a serious concern about these 
‘additional medicines’. One of the nurses, talking about the lack of proper medication reviews of 
these alternative medicines which had complicated the patient assessment and their clinical 
outcomes, explained: 
 
“The other issue is around GPs not reviewing the drugs required for our clients.  Also I think 
there’s a problem for healthcare workers too in not reviewing and really scrutinising what they 
are actually taking.  I’m not only taking the prescribed, I’m looking at complementary 
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medications too, over-the-counter medications or something that somebody has brewed up and 
made into a cocktail of their own.”  
 
(8) The ageing population in the North West region also resulted in a high number of elderly 
patient-related issues like poor eyesight, inabilities to self-administer medicine and poor 
comprehension of instructions due to old age and low literacy. Medication non-adherence was 
common among the elderly cancer patients because they were reluctant and resist to make 
changes due to unfamiliarity with their medications.  The nurse consultant pointed out that 
patients’ low drug compliance was one of the main reasons that led to the prevalence of DRPs: 
 
“I think there’s still for some of the frail older people if they’re, like sight impairment, they might 
go by the colours and feel of the medications without really knowing, being able to read the 
labels.. .  I think some clients there’s a resistance to change to medications, they actually like 
some of the things they are taking so they will have resistance.  Or there can be phobias about 
some of the medications when they might benefit, like opioids, morphine type drugs, they will 
have a phobia about those.  So we’ve got resistance and we’ve got phobias, so they’ll just 
suffer.” 
  
4.2.2. How the palliative care team manages DRPs 
 
In order to achieve optimal clinical effects, especially for pain relief in palliative care, the 
healthcare providers needed to perform complex calculations and remember conversion rules for 
opioids. The palliative team members needed to be trained to perform confidently in both the 
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hospital and community-based environments. However, it was felt that support and resources 
required to enhance the effectiveness of the North West palliative care service were lacking. The 
nurses agreed that the lack of skills and knowledge to perform opioid conversion were obvious, 
and opioid prescribing habits were thought to be a significant contributor to DRPs, in addition to  
polypharmacy, poor health literacy and OTC medication abuse. 
 
It was also pointed out during the group discussion that patients preferred to call a pharmacist for 
medication advice and assistance whenever they encountered DRPs. For the palliative care 
nurses, their methods for dealing with DRPs would depend on the level of urgency. For example, 
if the patient’s medication problems were acute, an ambulance would be called. Otherwise, the 
DRPs would be brought to a GP’s attention or discussed during the weekly clinical reviews 
among the palliative care team members. One nurse, referring to the methods to overcome 
patient DRPs, stated: 
 
“I’d always go back to the prescriber, whoever has prescribed, if there was a medication error 
or something that wasn’t right, to have a look to see who prescribed it in the first place.  If it’s at 
home or if a phone assessment, the first thing I would assess for is the level of danger, is there 
anything I need to do immediately, and that would be obviously an ambulance, a 000 call if I felt 
that was the reason.  If it was something that I assess and feel as if it could be sorted out with me 
discussing with their GP, or with the medical registrar who is here with us, I would do it that 
way.  If it’s something that could wait I would then bring it up in clinical review and then get 
back to them about what.  So it would be a matter of triaging whatever that drug related issue 
was.”  
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Two allied specialist health workers, an occupational therapist and a social worker proposed 
using the ‘triage’ system or referring the problems to palliative care nurses during their contacts 
with the patients. They also suggested the other nurses perform regular medication reviews either 
in hospital or home-based for the general wellbeing of the palliative care patients. A weekly 
clinical review, whereby team members gathered and discussed patient conditions and offered 
solutions were deemed as a crucial step to ensure a holistic palliative care. The nurse explained: 
 
“Also every week have a clinical review where we bring up discussions and any medication 
management issues there with our pharmacist, and with our doctors, and with out specialist 
nurses and whoever who help with, especially we’re talking medication here.” 
 
The introduction of the ‘yellow envelope’ system was praised by the team. This is a system 
whereby a paper envelope was used as a patient log and information centre. It contained all the 
required medical and drug information related to home-based patients. In times of emergency, 
ambulance and primary health providers could easily obtain the patient details required to carry 
out appropriate assessment and follow up. 
 
One of the nurses suggested that an instant access to online palliative pathway which provides 
updated medical and drug information during community visitation would be beneficial. 
Otherwise, bringing qualified and educated pharmacist into the palliative care team would be 
beneficial to provide drug and symptom knowledge. 
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In addition, it was also deemed crucial for the palliative care nurses and allied health workers to 
continuously receive updated health education. One nurse said this education needed to be 
‘ongoing’, provided by various medical professionals including locums. 
 
Since the nature of palliative care has changed tremendously and treatment of diseases has 
become complex, it was suggested that the medical institutions needed to provide well-designed 
palliative courses for the medical and nursing students in the universities in order to equip them 
with sufficient palliative care knowledge and awareness before they commenced in their 
professional roles. The participants also felt that palliative care team ought to be 
multidisciplinary in order to be effective and efficient to provide a holistic palliative care.  
 
All participants agreed that it would be a difficult task to raise an awareness of the importance of 
palliative care among the Tasmanian health service stakeholders.  
 
4.2.3. Pharmacist involvement within the team 
 
Many participants in the focus study agreed that the inclusion of a pharmacist in a palliative care 
team would be ‘amazing’. The nurses preferred to work with an accredited pharmacist who 
possessed sufficient experience in palliative care. Only an accredited pharmacist in palliative 
care would be able to conduct proper medication interference and review, reduce medication 
errors, educating the patients and team members in the palliative care community-based setting. 
The nurse consultant explained: 
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“One of the great valuable aspects of having a community pharmacist on our team is the fact 
that the pharmacist can give advice around the interactions of medications for our clients.  Many 
of our clients with life limiting illnesses have co-morbidities, and there is huge interaction 
between medications they might be prescribed for their particular or specific palliative 
diagnosis, in conjunction with their co-morbidities.  So it’s been very valuable for the pharmacist 
to be here to provide advice around the interactions of various medications.  And whether the 
medications might need rationalising.” 
 
One of the allied health workers felt that extra drug knowledge would be gained during home 
visitations if a pharmacist was available. The occupational therapist stated: 
 
“From an allied health perspective, it’s really useful having a pharmacist on the team to explain 
medications in layman’s terms, in a way that an allied health professional would understand 
who, is not necessarily aware of all the medications.  Over time that changes obviously with 
more education.” 
 
It was also mentioned by one palliative care nurse that pharmacist participation would reduce the 
bill and cost burdens of the patients due to their extensive drug knowledge and familiarity with 
drug pricing.  
 
“It’s been really valuable having the community pharmacist on a multidisciplinary team, as in 
updating us and keeping the rest of the team on relevant medications for patients, as well as able 
to review a patient’s drug chart and speak about unnecessary medications that someone may be 
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taking that’s in a terminal phase, or deteriorating phase.  And leaving that burden of people 
having to take more and more tablets for no reason.” 
 
 
Themes 
 
Key findings 
Factors contributing to DRPs encountered 
during palliative care delivery 
1. Suboptimal drug management 
2.geographical disadvantage causing short 
supply of drugs 
3.Potential drug abuse, e.g in low socio-
economic areas 
4. Different prescribing habits by 
community GPs. 
5. A high turnover of medical practitioners 
and health professionals 
6. Low health literacy, lack of drug 
education and knowledge 
7. Lack of home medication review 
8. Patient frailty in an aging population 
 
Opinions on DRP management 1. Adequate Skills and knowledge .eg 
Opioid conversions 
2. Continuing education for the palliative 
care team members 
3. Reliable supports and resources 
4. Carry out regular medication reviews 
(hospital and community)  
5. ‘Yellow Envelope” 
6. Utilise online palliative pathway 
7. Bring in highly qualified health 
professional e.g pharmacist 
8. Form a Multidisciplinary team 
 
Opinions on pharmacist inclusion in the 
palliative care team 
Requirement: Need to be accredited, 
experienced. 
 
Benefits: 
1. Give advice to patients, prevent drug 
interactions 
2. Provide drug knowledge to patents who 
are home-based. 
3. Reduce bill and cost burdens 
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4. Updating drug knowledge to co-workers 
in a multidisciplinary team 
 
 
Table 8. Reponses of the focus group participants to the main discussion themes 
 
Although it would be cost effective to include a pharmacist in the team, the inclusion of a 
pharmacist would make their palliative care team ‘multidisciplinarily’ effective. The nature of 
regional and rural palliative care pharmacy practice would be difficult and appeared to be more 
challenging compared to those who work in urban hospitals. This was deemed to be due to the 
vast geographical area which would lead to increased travelling time. This served as a workforce 
deterrence for any potential pharmacist who would consider working in the North West 
community-based palliative care service. 
 
One of the nurses said the availability of a pharmacist most likely would only benefit some areas, 
but not the whole region. Smaller and remote areas would still not receive instant and regular 
coverage of palliative care service. 
 
Finally, the participants collectively agreed that a lack of funding would serve as the biggest 
obstacle to including a pharmacist as a permanent member in their palliative care team.  
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5 Discussion 
 
Our studies suggest that DRPs are common in the North West palliative care setting. The 
retrospective study highlighted three types of DRP, Adverse drug reactions, dosage 
mismanagement and noncompliance with drug use were the most common DRPs experienced by 
our sample patients. The patients’ clinical outcomes showed significant improvement after 
receiving palliative care as symptoms such as pain, shortness of breath, constipation, 
nausea/vomiting, fatigue, appetite problems and insomnia were reduced in occurrence. Weight 
loss and delirium appeared to produce a non significant downward trend during the data 
collection period. Other symptoms such as dysphagia and confusion/hallucination did not 
produce a positive trend of response. These symptoms remained despite active drug and medical 
management provided. 
 
Several palliative medicines were associated with DRPs. This was particularly important when 
multiple drugs were used in palliative care which would lead to the prevalence of DRPs (69). 
The patients were given opioid analgesics for pain relief, and a series of dose titrations were 
often needed in order to reach the optimal analgesic effect. The occurrence of DRPs associated 
with palliative medicines indicated the palliative care team needed to perform regular and 
accurate medication monitoring. 
 
There are several potential reasons for the high prevalence of DRPs among the palliative care 
patients. 
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1. As patients’ cancer diseases progressed, the number of prescribed medication also 
increased during palliation. The increasing use of opioids and psychotropic medications 
in palliative care contributed to the increase of drug toxicity and adverse effects (69). 
Their combination usage with anticancer drugs gave rise to DRPs and patient compliance 
issues.  
 
2. Although multiple drug management was deemed important during palliative care, 
often it was difficult to achieve optimal pain and symptom relief due to DRPs. The 
situation became even more challenging when the same patients had impaired hepatic or 
renal function (70, 71).  
 
3. The prevalence of DRPs usually indicated the progression of cancer diseases and 
deterioration of the patients’ health issues. Increased frailty of the patients as their 
conditions deteriorated resulted in a higher rate of DRPs among these patients, despite the 
provision of palliative care services.  Although it was identified that patients’ 
comorbidities and polypharmacy contributed to DRPs, treatment of co-morbidities could 
be considered as subordinate in this terminal stage. Chronic diseases such as hypertension 
and diabetes could potentially be left untreated (or treated less intensively), when the 
primary goal of the palliative care team would be totally focused on patient comfort from 
cancer deterioration. Therefore, symptoms related to co-morbidities could be treated sub-
optimally and appear as DRPs in our study.  
 
4. Apart from the difficulties associated with managing complex disease states, the high 
incidence of DRPs could also be due to geographical and demographic barriers factors 
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[72]. The North West palliative cancer patients were often home-based and required 
frequent home assessments by the palliative care team. The inconvenience of transport 
and vast distance resulted in inadequate medical monitoring of the home-based patients. 
Walker et al in their report stated the North West palliative care service was not fully 
utilised because of issues relating to distance and role delineation (47). Although 
telephone communication had been actively utilised by the palliative care team for 
medication counselling, it was still considered as insufficient to address the complex 
palliative problems faced by the patients and their family members.  
 
Previous studies have described the barriers and challenges faced by regional palliative care 
service providers. For example, has been reported that more than 90% of elderly cancer patients 
suffered from at least one comorbidity, and 30–40% of those comorbidities were severe [21]. 
Similarly, Hilmer et al [31] found that elderly patients were at high risk of experiencing DRPs 
when they took multiple drugs for chronic disease treatment and cancer chemotherapy.  
 
There are a number of limitations to the retrospective study. Throughout the study, the recording 
of patients’ medical and drug information was not consistent. Sometimes, there were limited 
descriptions on the patient’s status. This could be due to a lack of regular home-based medical 
visitation by healthcare providers or incomplete patient journal data entry while accessing the 
patients. It was not uncommon for the patients and their carers to give misleading description of 
their cancer conditions, particularly at the stage of admission due to a lack of disease or drug 
knowledge (72). The denial of symptoms by the patients, or the deterioration of their condition 
during home visitation could also have made our medical review less accurate. Patient 
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hospitalisation in other hospital(s), other than the North West Regional Hospital and Mersey 
Community Hospital, was also one of the factors which resulted in incomplete medical record or 
even zero data entry for a period of time in the patient record.  On some occasions, patients died 
before the completion of assessments. 
 
We also observed a number of patients after their admission to palliative care continuing to be 
treated with their cancer chemotherapy and also their chronic diseases. It is possible that 
chemotherapy and comorbidities treatment were to some extent responsible for drug toxicity and 
adverse effects instead of the palliative medicines (73). It was impossible to determine whether 
symptoms like fatigue, hallucination, vomiting or loss of appetite were due to the side effects of 
chemotherapy or palliative medicines, since there was no description about the cause of 
symptoms. Even patients’ pain relief was challenging to monitor, because the pain might not be 
from the lack of analgesia, but due to the progression of cancer. 
 
This study only reviewed the first three contacts of patients with the palliative care team. Further 
research is needed to extend the study time frame in order to explore the complete palliative care 
service received by the patients throughout their cancer journey. The inclusion criteria could be 
expanded to include patients in hospital and other hospice care facilities, instead of only looking 
at home-based patients. 
 
The retrospective study has identified that patients in North West Tasmania require an effective 
community-based palliative care service to address their DRPs and complications of the care 
provided (6). The present palliative care service currently utilises the combined efforts of a 
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palliative care doctor, palliative care trained nurses and community nurses for home visitation. 
North West Tasmania’s hospitals are still not equipped with designated beds for palliative care 
patients, and most of the cancer patients in this region are forced to stay at home waiting for 
community palliative care service delivery (6). There are insufficient qualified palliative care 
specialist resources to provide interdisciplinary palliative care to the patients and family 
members. Perhaps by incorporating a pharmacist in the team, DRPs and symptomatic 
complication could be reduced. 
 
Palliative care team members’ recommendations  
 
In our focus group study, medication mismanagement was identified as the most common 
contribution to DRPs in palliative care service. Medication errors were mainly due to 
noncompliance and lack of understanding of health and medication information. 
 
It was identified that many rural palliative care patients faced difficulties associated with reduced 
healthcare provider input and limited knowledge of their medications. They had fewer or zero 
visits from physicians and specialists. The lack of palliative care information could also be due to 
reduced health care provider input and limited choices for home care. As counselling and 
education were crucial to enhance patient compliance, it was a challenge for the palliative care 
team to ensure the patients would receive accurate information throughout their palliative care 
services. 
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Besides the above challenges, the palliative team members also suggested making full use of the 
Tasmanian Health pathway Direct Assess Website for instant resources access while providing 
their community home visits or even after hour services.  
 
The demand for a collaborative approach between palliative care providers including community 
GPs and other health professionals was also emphasised. There was a common understanding 
among the team members that healthcare professionals in the North West needed to improved 
workplace communications and collaboration in order to provide better clinical outcomes for 
community palliative care. It was pointed out that the shortage of skilled health professionals and 
high turnover of doctors was an impediment factor for an effective palliative care service. Hence, 
recruiting more palliative care specialists was considered as being important to reduce the risk of 
medication misadventure.  
 
The inclusion of a pharmacist in the service delivery was perceived to be beneficial, particularly 
in patient’s medication and symptom control. A pharmacist’s participation could also potentially 
update the team with the latest drug knowledge and price information. Continuing education 
could be provided to health care workers by the pharmacist about the latest knowledge of 
palliative medicines. 
 
More importantly, with the pharmacist expertise, the cost-effectiveness and cost-benefit of 
medications used in palliative care would be better determined. In this way, avoidance of patient 
admissions to hospitals or long-term care facilities expenses through effective symptom control 
is a desirable outcome. 
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Many previous reviews have suggested that the pharmacist is particularly of value to the overall 
functioning of the team by identifying potential DRPs and improving symptom control. Lee et al 
[35] stated pharmacist intervention was ‘pivotal’ for the patients to achieve a positive clinical 
outcome. Hussainy et al [34] claimed that medication reviews by a pharmacist either by home 
visitation or telephone would bring a significant impact to patients’ care. The patients/carers 
were given up-to-date medication counselling and education to make them feel confidence in the 
usage of medications [34]. This was considered to be important because a reduction in 
medication errors meant reduction in hospital admissions. This would in term reduce the cost of 
medical care for the patients. 
 
There were limitations to the focus study. The North West palliative care service was operated 
by a relatively small team which comprised of nurses and doctors. Occasionally, the unit would 
hire a temporary pharmacist when the funding allowed.  Therefore, the nurses’ views were 
dominant. There was a lack of multidisciplinary opinions from other allied health workers. In 
addition, patients and carers were not involved in the study, with respect to their opinions about 
DRPs prevalence and the potential benefits of pharmacist inclusion in palliative care.  
 
Despite the limitations of the focus study, the palliative care team members supported the 
inclusion of pharmacist in the North West palliative care team, because pharmacist expertise 
could potentially benefit the palliative care service providers, patients and carers. The team also 
emphasised the importance of an accredited palliative care pharmacist to take charge of the home 
medication reviews. 
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Finally, all participants agreed that the inclusion of a pharmacist in the palliative care team 
would largely dependent on the allocation of funding. A permanent full time position would be 
ideal but the funding for this position would put pressure in an already stretched state 
government health service budget. This situation is also unlikely to change without recognition 
by the government and health service administrator of the value of pharmacist involvement with 
the palliative care service. 
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6 Conclusion 
 
There is a high prevalence of DRPs among the cancer population in North West Tasmania.The 
challenges faced by the palliative care team members in this region have highlighted the need of 
a palliative care pharmacist. The North West palliative care team recognised pharmacist 
interventions as one of the options to potentially improve palliative patient care and reduce 
DRPs, and the inclusion of a pharmacist would likely improve the quality of life for patients 
receiving community-based palliative care services in North West Tasmania. 
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8 Appendices 
 
 
 
 
APPENDIX 1 
 
Patient code: 
Demographics 
Age: ____    M/F:____    Postcode:______ 
*1st contact:       *Death: 
Patient Related Factors 
Weight ______   Height______     
 
Living Status 
□ Living alone  □Living with carer/family member □ in supported residential services  □ poor 
carer support or carer concerns   
 
Medical Conditions 
Main Diagnosis (requiring palliative care): Cancer □    Others □ 
Details: ____________________________________________________ 
 
Comorbid Conditions:  
 
□Myocardial infaction 
□ Congestive heart failure 
□ Peripheral vascular disease 
□Hemiplegia or paraplegia 
□Dementia 
□Chronic pulmonary disease 
□ Peptic ulcer disease 
□ Diabetes without chronic complications 
□ Diabetes with chronic complications 
□ Renal disease 
□ Any malignancy, including leukemia and lymphoma 
□ Metastatic solid tumor 
□ Mild liver disease 
□Moderate or severe liver disease 
□ AIDS/HIV 
 
Comments: __________________________________________________________ 
*KF:        *Phase:        *SPZA:            
Renal function: 
□ Renal Failure 
Creatinine Clearance: ____________   eGFR:______________________ 
Liver Function Tests:  
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□ Liver Disease   
Albumin:_________  Bilirubin: _________ Gamma 
GT:_______________AST/SGOT:_____________ ;ALT/SGPT: _________ ALP: ______ 
 
*CE (clinical examination) page (1st contact) : 
*Medication Record:  
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APPENDIX 2 
 
Medication Record Form (1st Contact) 
Patient Code: 
Date of first contact: ______________________________________ 
Medications on first contact 
Symptom and Type 
of drug 
Drug Dose (mg/day) Comments 
Pain    
Non Opioids    
    
Opioids    
    
Neuropathic Pain    
    
Antidepressant    
    
Anticonvulsant    
    
Corticosteroid    
    
Nausea/Vomiting    
Antiemetic    
    
Constipation    
Laxative    
    
Others    
Anti ulcers    
Hyperthyroidism    
Hormone    
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Hormone    
    
    
    
    
 
 
 
Medication Record Form (2nd Contact) 
Patient Code: 
Date of second contact: ___________________________ 
Medications on second contact 
Symptom and Type 
of drug 
Drug Dose (mg/day) Comments 
Pain    
Non Opioids    
    
Opioids    
    
Neuropathic Pain    
    
Antidepressant    
    
Anticonvulsant    
    
Corticosteroid    
    
Nausea/Vomiting    
Antiemetic    
    
Constipation    
Laxative    
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Others    
Bronchodilator    
Antibacterial    
    
    
    
    
    
    
    
    
 
 
 
Medication Record Form (3rd Contact) 
Patient Code: 
Date of third contact: _______________________ 
Medications on second contact 
Symptom and Type 
of drug 
Drug Dose (mg/day) Comments 
Pain    
Non Opioids    
    
Opioids    
    
Neuropathic Pain    
    
Antidepressant    
    
Anticonvulsant    
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Corticosteroid    
    
Nausea/Vomiting    
Antiemetic    
    
Constipation    
Laxative    
    
Others    
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APPENDIX 3 
 
DRPs Assessment sheets 
Patients’ problems from the medical notes will be described. Classification of DRPs is done 
by ticking the relevant categories and subcategories will be written respectively as detailed 
comments. (Refer to Appendix 4 for DRPs classification tool) 
 
Date: ____________________________________________________ 
Description of problem: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
___ 
 
 
Classification: □ D ___________________________________________________________ 
                        □ O  ___________________________________________________________ 
                        □ C ___________________________________________________________  
                        □ U ___________________________________________________________ 
                        □ M ___________________________________________________________  
                        □ E ___________________________________________________________  
                        □ N ___________________________________________________________  
                        □ T ___________________________________________________________ 
 
Date:  
Description of problem:  
____________________________________________________________________________ 
___________________________________________________________________________ 
Classification: □ D ___________________________________________________________ 
                        □ O  ___________________________________________________________ 
                        □ C ___________________________________________________________  
                        □ U ___________________________________________________________ 
                        □ M ___________________________________________________________  
                        □ E ___________________________________________________________  
                        □ N ___________________________________________________________  
                        □ T ___________________________________________________________ 
 
 
Date: ______________________________________________________________________ 
Description of problem: _______________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
Classification: □ D ___________________________________________________________ 
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                        □ O  ___________________________________________________________ 
                        □ C ___________________________________________________________  
                        □ U ___________________________________________________________ 
                        □ M ___________________________________________________________  
                        □ E ___________________________________________________________  
                        □ N ___________________________________________________________  
                        □ T ___________________________________________________________ 
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APPENDIX 4 
 
FOR REFERENCE ONLY 
Classification of Drug Related Problems using the D.O.C.U.M.E.N.T   
 
D Drug selection   
   □  D1 Duplication  
   □  D2 Drug interaction  
   □  D3 Wrong drug  
□ D4 Incorrect strength  
   □  D5 Inappropriate dosage form  
   □  D6 Contraindications apparent  
   □  D7 No indication apparent  
        D8 Other drug selection problem __________________________________ 
O Over or under-dose    
    □ O1 Prescribed dose too high 
    □ O2 Prescribed dose too low  
    □ O3 Incorrect or unclear dosing instructions  
        O0 Other dose problem _________________________________________ 
C Compliance   
□     C1 Taking too little 
□     C2 Taking too much  
□      C3 Erratic use of medication  
□     C4 Intentional drug misuse (Including OTCs)  
□     C5 Difficulty with dosage form  
        C0 Other compliance problem ____________________________________ 
U Under-treated or Untreated indication    
□     U1 Condition not adequately treated 
□     U2 Condition untreated  
□     U3 Preventive therapy required  
        U0 Other untreated indication problem _______________________________________ 
M Monitoring required      
□     M1 Laboratory monitoring 
□     M2 Non-laboratory monitoring  
       M0 Other monitoring problem_____________________________________________ 
E Education or Information   
□    E1 Patient requests drug information  
□    E2 Patient requests disease management advice  
       E0 Other education or information problem _____________________________________ 
N Not classifiable   
□     N0 Clinical interventions that cannot be classified under another category  
T Toxicity or adverse reaction   
□   T1 Toxicity, allergic reaction or adverse effect present 
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Classification of Drug Related Problems using the D.O.C.U.M.E.N.T   
 
Classification Definition 
D Drug selections 
O Over or Under-dose    
C Patients and carers Compliance 
U Under-treated or Untreated indication    
M Monitoring requirement (Lab or Non-Lab) 
E Education, counselling and information 
N Not Classifiable (transport, delivery of medication) 
T Toxicity 
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APPENDIX 5 
 
 
 
 
 
 
 
 
 
 
To explore the role of pharmacist participation in community-based palliative care service 
in North West Tasmania 
Information Sheet for participants 
 
 
You are invited to participate in a research study, conducted by the University of Tasmania, 
School of Medicine. Before you decide whether or not you wish to participate in this study, it is 
important for you to understand why the research is being done and what it will involve. Please 
take the time to read the following information carefully and discuss it with others if you wish. 
This research forms part of Johnny Hii’s Master of Pharmacy project, under the supervision of 
Assoc Prof Luke Bereznicki, Dr Leanne Chalmers and Dr Thiru Thirukkumaran. 
 
1. What is the purpose of this study? 
In palliative care, drug-related problems (DRPs) are very common. It is especially difficult to 
manage DRPs in a community-based setting. Through this focus group discussion, we hope to 
find out about your experience in addressing these challenges in order to provide a positive 
clinical outcome for patients receiving palliative care. 
 
This discussion aims to identify -   
I. The North West palliative care service members’ perceptions of current DRP 
management. 
II. Your experiences and opinions in monitoring DRP management in a community-based 
palliative care setting. 
III. If there is a role for pharmacists to be more involved in the community-based palliative 
care setting. 
 
 
2. Why have I been invited to participate in this study? 
You have been invited to take part because you provide community-based palliative care service 
in the North West Tasmania region. 
 
3. What does this study involve? 
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You will be asked to attend a 1-2 hour focus group session to share about your experience as a 
palliative care service provider in North West Tasmania.  You will be encouraged to express 
your opinions on the following: 
 
 
I. Brief introduction about yourself and your discipline so we know a little more about the 
health professions taking part in this focus group.  
II. Questions on DRPs faced by patients and the palliative care team, and your approach to 
effectively reduce DRPs. 
III. Your views on the potential involvement of pharmacist, from both the perspectives of the 
team and the patients. 
 
The focus group discussion will be tape recorded to ensure that your comments are accurately 
recorded. 
4. What happens if I don’t want to take part in this study, or if I want to withdraw later? 
Participation is entirely voluntary. While we would be pleased to have you participate, we respect 
your right to decline. There will be no consequences to you if you decide not to participate. If you 
decide to discontinue participation at any time, you may do so without providing an explanation. 
 
5. What are the benefits of this study? 
It is hoped that through the focus group discussion, shared experience from the participants will 
help identifying different issues and challenges faced by the palliative care service providers, 
patients and carers. The views from the participants will be seek to inform the future incorporation 
of a pharmacist in the North West Palliative Care team. 
 
6. Are there any potential risks associated with this study? 
This is a focus group discussion. There are no potential risks associated with the researcher and 
participants. Each participant will be assigned with a unique identifier to ensure anonymity. 
 
7. How will my confidentiality be protected? 
Only information required to meet the aims of the study will be audiotaped, transcribed and 
analysed. The information collected will be treated confidentially and you will be given a unique 
identifier, to ensure your identity is protected. Any reports or publications that result from this 
study will not contain reference to any identifiable person. All information collected as part of this 
study will be kept in secure storage in the Division of Pharmacy, School of Medicine, University 
of Tasmania, and will be destroyed after 5 years in line with University of Tasmania regulations. 
 
 
8. What should I do if I want to know more about the research before I decide? 
When you have read this information, if you have any queries regarding this discussion, please do 
not hesitate to contact the investigator listed below: 
 
 
 
Johnny Hii 
Research Candidate in Pharmacy 
	93	
Pharmacy, School of Medicine, 
Private Bag 26, University of Tasmania, Hobart, TAS 7001 
Tel: 0458 138488 E-mail: johnny.hii@utas.edu.au 
 
Assoc Prof Luke Bereznicki 
Chief Investigator 
Pharmacy, School of Medicine, 
Private Bag 26, University of Tasmania, Hobart, TAS 7001 
Tel: 6226 2195 E-mail: luke.bereznicki@utas.edu.au 
 
 
Dr Leanne Chalmers 
Investigator 
Pharmacy, School of Medicine, 
Private Bag 26, University of Tasmania, Hobart, TAS 7001 
Tel: 6226 1095 E-mail: leanne.chalmers @utas.edu.au 
 
 
Dr Thiru Thirukkumaran 
Investigator 
Palliative Care Services- THO Northwest 
UTAS Rural Clinical School, Burnie, TAS 7320 
Tel: 64304561 E-mail: thiru.thirukkumaran@utas.edu.au 
 
 
9. If I agree to take part, what happens next? 
You will need to sign and return the attached consent form. 
 
10. Who should I contact if I have concerns about the conduct of this study? 
 
This project has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee. If you have any concerns of an ethical nature, or complaints about the manner in which 
the study is conducted, you may contact the Executive Officer of the Human Research Ethics 
Committee (Tasmania) Network on (03) 6226 7479 or human.ethics@utas.edu.au. Please quote 
the ethics reference number XXXXX. 
 
 
Thank you for taking the time to consider taking part in this study. 
This information sheet is for you to keep. 
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APPENDIX 6 
 
 
Exploration of the role of a pharmacist in the community-based palliative care 
service in North West Tasmania 
 
Participant Consent Form 
 
1. I acknowledge that the nature, purpose and contemplated effects of the project so far as it 
affects me, have been fully explained to my satisfaction by the research worker and my 
consent is given voluntarily. 
 
2. I have read and understood the ‘Information Sheet’ for this study. 
 
3. The details of the study methods have also been explained to me. I understand that I will be 
asked to attend a 1-2 hour focus group session to share my experiences of drug-related 
problems as a palliative care service provider in North West Tasmania, and my opinions 
about the potential involvement of pharmacist on the team. I understand that the focus group 
discussion will be tape recorded to ensure that my comments are accurately recorded. 
 
4. I have been informed that the aim of the study is to improve the future delivery of palliative 
care services. 
 
5. I understand that participation is entirely voluntary. There are no consequences if I decide 
not to participate.  
 
6. I agree that research data gathered for the study may be published provided that I cannot be 
identified. 
 
7. I understand that the researchers will maintain my identity confidential and that any 
information I supply to the researchers will be used only for the purposes of the research. I 
understand that I am required to maintain the confidentiality of the identities and responses 
of the other members of the focus group. While all of the focus group members will be 
advised of this requirement, I acknowledge that the researchers cannot be held responsible 
for the other focus group members maintaining this confidentiality. 
 
8. Any questions I have asked have been answered to my satisfaction. 
 
9. I understand that I will be given a signed copy of this Participant Information Sheet and 
consent form. I am not giving up my legal rights by signing this consent form. 
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10. I understand that the study will be conducted in accordance with the latest versions of the 
National Statement on Ethical Conduct in Human Research 2007 and applicable privacy 
laws. 
 
Name of participant: __________________________________        
 
Signature of participant: ___________________ Date: _______  
 
11.  I have explained this project and the implications of participation in it to the participant and 
I believe that the consent is informed and that he/she understands the implications of 
participation. 
 
 
Name of investigator: ___________________________________        
 
Signature of investigator: ___________________ Date: ________          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	96	
APPENDIX 7 
 
 
Question Guide 
 
Themes 
 
• DRPs encountered by the palliative care service 
• The approach to DRP management by the palliative care service 
• Views on potential inclusion of a pharmacist in the team 
 
The questions for the focus group participants are: 
 
1. The palliative care population is considered to be at high risk of drug-related problems 
(DRPs). Describe the type of DRPs faced by patients, and the team during community-based 
palliative care such as drug dosage and side effects monitoring, patient adherence to medication 
regimen etc. 
 
-What are the main DRPs? 
-What factors contribute to the DRPs? 
-How significant are the DRPs? 
 
2. How does the palliative care team cope with the DRPs and how do you overcome them? 
 
- Please describe your approach to DRP management during community-based practice. 
-What are the obstacles and barriers faced by the patients, health professionals, family members 
and carers during DRP management of a community-based patient? 
 
 
3. What are your perceptions and views on the pharmacist service in the context of community-
based palliative care? 
 
- What roles/activities could be undertaken by a pharmacist on the palliative care team?  
-  What potential advantages can you envisage from involvement of a pharmacist on the team 
from the perspective of a) the team, and b) the patients? 
- What barriers are there to the involvement of a pharmacist? 
- Overall, would you be supportive of a pharmacist on the palliative care team? 
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APPENDIX 8 
 
Patient medications and the prevalence of DRPs for each contact 
 
 
       Drugs used                  P Values 
DRP_OA 
N=100 
n (%) 
DRP_C1 
N=99 
n (%) 
DRP_C2 
N=76 
n (%) 
OA C1 C2 
Analgesic Paracetamol (R) 
 
 
Yes 
N=30 (OA) 
N=19 (C1) 
N=14 (C2) 
 
15 (50.0) 
 
11 (57.9) 
 
9 (64.3) 0.793 0.897 0.258 
 Paracetamol 
(PRN) 
 
Yes 
N=16 (OA) 
N=10 (C1) 
N= 4 (C2) 
 
12 (75.0) 7 (70.0) 3 (75.0) 0.045 0.366 0.317 
 Paracetamol 
+codeine (R) 
 
Yes 
N=5 (OA) 
N=3 (C1) 
N=4 (C2) 
 
3 (60.0) 56 (56.6) 2 (50.0) 0.713 0.410 0.978 
 Any paracetamol Yes 
N= 49 (OA) 
N= 30 (C1) 
N= 19 (C2) 
 
 
29 (59.2) 18 (60.0) 12 (63.2) 0.159 0.649 0.208 
NSAIDs Any NSAIDs 
NSAIDs (PRN) 
Yes 
N=15 (OA) 
N=8 (C1) 
N=4 (C2) 
 
 
9 (60.0) 5 (62.5) 2 (50.0) 0.501 0.724 0.978 
Opioids Morphine (R) Yes 
N= 14 (OA) 
N= 19 (C1) 
N= 30 (C2) 
 
 
6 (42.9) 9 (47.4) 14 (46.7) 0.460 0.368 0.572 
 Morphine (PRN) Yes 
N= 25(OA) 
N= 31 (C1) 
N= 18 (C2) 
 
10 (40.0) 17 (54.8) 10 (55.6) 0.166 0.815 0.634 
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 Any morphine Yes 
N= 32 (OA) 
N= 40(C1) 
N= 39 (C2) 
 
14 (43.8) 21 (52.5) 20 (51.3) 0.257 0.502 0.912 
 Oxycodone (R) Yes 
N= 34 (OA) 
N= 34 (C1) 
N= 17 (C2) 
 
 
21 (61.8) 19 (55.9) 9 (52.9) 0.161 0.921 0.831 
 Oxycodone 
(PRN) 
Yes 
N= 30(OA) 
N= 26(C1) 
N= 16(C2) 
 
19 (63.3) 20 (76.9) 10 (62.5) 0.138 0.015 - 
 Oxycodone/nalo
xone 
Yes 
N= 2 (OA) 
N= 1 (C1) 
N= 4 (C2) 
 
2 (100.0) 1 (100.0) 1 (25.0) 0.170 0.378 0.291 
 Any oxycodone Yes 
N= 47 (OA) 
N= 45 (C1) 
N= 29 (C2) 
 
30 (63.8) 28 (62.2) 16 (55.2) 0.026 0.300 0.535 
 Hydromorphone 
(R) 
Yes 
N= 14 (OA) 
N= 13 (C1) 
N=  9  (C2) 
 
11 (78.6) 7 (53.8) 3 (33.3) 0.032 0.832 0.268 
 Hydromorphone 
(PRN) 
Yes 
N=  5 (OA) 
N= 10 (C1) 
N= 8 (C2) 
 
2 (40.0) 6 (60.0) 3 (37.5) 0.582 0.817 0.431 
 Any 
hydromorphone 
Yes 
N= 14 (OA) 
N= 16 (C1) 
N= 13 (C2) 
 
11 (78.6) 9 (56.3) 5 (38.5) 0.032 0.978 0.333 
 Fentanyl (R) Yes 
N= 9  (OA) 
N= 7  (C1) 
N=10 (C2) 
 
4 (44.4) 1 (14.3) 4 (40.0) 0.634 0.019 0.469 
 Fentanyl (PRN) Yes 
N= 1 (OA) 
N= 1 (C1) 
N= 0 (C2) 
 
0(0.0) 0 (0.0) -- 0.296 0.251 - 
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 Any fentanyl Yes 
N= 9 (OA) 
N= 7 (C1) 
N=10 (C2) 
 
4 (44.4) 1 (14.3) 4 (40.0) 0.634 0.019 0.469 
 Any opioids Yes 
N= 76 (OA) 
N= 87 (C1) 
N= 71 (C2) 
 
42 (55.3) 48 (55.2) 35 (49.3) 
 
0.245 0.451 0.317 
Benzodiaze
pines 
Midazolam (R) Yes 
N= 7  (OA) 
N= 15 (C1) 
N= 31 (C2) 
 
 
2 (28.6) 7 (46.7) 11 (35.5) 0.198 0.401 0.027 
 Midazolam 
(PRN) 
Yes 
N= 5  (OA) 
N= 11 (C1) 
N= 15 (C2) 
 
2 (40.0) 8 (72.7) 6 (40.0) 0.582 0.251 
 
0.356 
 Any midazolam Yes 
N= 9 (OA) 
N=19 (C1) 
N=32 (C2) 
 
2 (22.2) 10 (52.6) 12 (37.5) 0.061 0.700 0.049 
 Clonazepam (R) Yes 
N= 5 (OA) 
N= 3 (C1) 
N= 2 (C2) 
 
5 (100.0) 2 (66.7) 0 (0.0) 0.028 0.720 0.146 
 Clonazepam 
(PRN) 
Yes  
N= 1 (OA) 
N= 6 (C1) 
N= 4 (C2) 
 
1 (100.0) 5 (83.3) 3 (75.0 ) 0.334 0.172 0.317 
 Any clonazepam Yes 
N=6 (OA) 
N=9 (C1) 
N=6 (C2) 
 
6 (100.0) 7 (77.8) 3 (50.0) 0.015 0.178 0.973 
 Any 
benzodiazepines 
Yes 
N=27 (OA) 
N=38 (C1) 
N=44 (C2) 
 
15 (55.6) 22 (57.9) 19 (43.2) 0.665 0.833 0.122 
AntiNausea Haloperidol (R) Yes 
N= 16(OA) 
N= 24(C1) 
N= 38(C2) 
 
7 (43.8) 8 (33.3) 15 (39.5) 0.471 
 
0.008 0.049 
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 Haloperidol 
(PRN) 
Yes 
N= 10 (OA) 
N= 5 (C1) 
N= 13 (C2) 
 
3 (30.0) 2 (40.0) 4 (30.8) 0.142 0.443 0.115 
 Any haloperidol Yes 
N=19 (OA) 
N=26 (C1) 
N=43 (C2) 
 
7 (36.8) 10 (38.5) 17 (39.5) 0.142 0.030 0.025 
 Metoclopramide 
(R) 
Yes 
N= 15 (OA) 
N= 16 (C1) 
N= 11 (C2) 
 
5 (33.3) 9 (56.3) 7 (63.6) 0.117 0.978 0.352 
 Metoclopramide 
(PRN) 
Yes 
N= 9 (OA) 
N= 5 (C1) 
N= 2 (C2) 
 
8 (88.9) 2 (40.0) 0 (0.0) 0.020 0.443 0.146 
 Any 
metoclopramide  
Yes 
N=24 (OA) 
N=21 (C1) 
N=13 (C2) 
 
13 (54.2) 11 (52.4) 7 (53.8) 0.807 0.663 0.801 
 Ondansetron (R) Yes 
N= 7 (OA) 
N= 7 (C1) 
N= 5 (C2) 
 
4 (57.1) 3 (42.9) 4 (80.0) 0.778 0.448 0.174 
 Ondansetron 
(PRN) 
Yes 
N= 4 (OA) 
N= 2 (C1) 
N= 0 (C2) 
 
3 (75.0) 2 (100.0) -- 0.347 0.211 - 
 Any ondansetron Yes 
N=11 (OA) 
N=  9 (C1) 
N=  5 (C2) 
 
7 (63.6) 5 (55.6) 4 (80.0) 0.413 0.949 0.174 
 Any anti Nausea Yes 
N=48 (OA) 
N=49 (C1) 
N=53 (C2) 
 
25 (52.1) 24 (49.0) 24 (45.3) 0.987 0.132 0.148 
Laxatives Coloxyl & 
Senna (R) 
Yes 
N= 17 (OA) 
N= 15 (C1) 
N= 10 (C2) 
 
10 (58.8) 6 (40.0) 7 (70.0) 0.536 0.160 0.189 
	101	
 Coloxyl & 
Senna (PRN) 
Yes 
N= 5 (OA) 
N= 3 (C1) 
N= 0 (C2) 
 
2 (40.0) 2 (66.7) -- 0.582 0.720 - 
 Any  Coloxyl & 
Senna  
Yes 
N=22 (OA) 
N=18 (C1) 
N=10 (C2) 
 
12 (54.5) 8 (44.4) 7 (70.0) 0.787 0.251 0.189 
 Macrogol (R) Yes 
N= 6 (OA) 
N= 9 (C1) 
N= 4 (C2) 
 
2 (33.3) 6 (66.7) 2 (50.0) 0.345 0.521 0.978 
 Macrogol (PRN) Yes 
N= 6 (OA) 
N= 5 (C1) 
N= 5 (C2) 
 
3 (50.0) 3 (60.0) 3 (60.0) 0.919 0.874 0.666 
 Any macrogol  Yes 
N=12 (OA) 
N=13 (C1) 
N= 9 (C2) 
 
5 (41.7) 9 (69.2) 5 (55.6) 0.445 0.323 0.754 
 Any Laxative Yes 
N=31 (OA) 
N=26 (C1) 
N=16 (C2) 
 
17 (54.8) 15 (57.7) 9 (56.3) 0.703 0.893 0.615 
R = Regular dose 
PRN = When required 
Any = Any form of administration, can be either regular or when required, or both 
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